



СК-ФАРМАЦИЯ



KAZAKH INVEST
NATIONAL COMPANY

INVESTMENT GUIDE BOOK

Content


Procedures for purchasing pharmaceuticals and medical devices from domestic manufacturers;.....	p. 3
Standard of state service for pharmaceuticals and medical devices registration;.....	p. 14
Statutory and regulatory enactments;.....	p. 16
ANNEX 1 Information and Analytical unit of SK-Pharmaceuticals	p. 19
ANNEX 2 List of items on the Single Distributor List for 2021, not declared by domestic manufacturers;.....	p. 23
ANNEX 3 Comprehensive plan for the development of the pharmaceutical and medical industries for 2020-2025 JSC;.....	p. 40
ANNEX 4 Preferences for investment projects of «KAZAKHINVEST»	p. 51
ANNEX 5 Development of the pharmaceutical industry in Kazakhstan (Minister of Industry and Infrastructure Development);	p. 67
ANNEX 6 Analytical review of the pharmaceutical industry of JSC «QAZINDUSTRY»;	p. 72
ANNEX 7 How to become a member of SEZ? QAZINDUSTRY".	p. 81
ANNEX 8 SEZ Park of Innovative Technologies	p. 84
Contacts list;	p. 90



СК-ФАРМАЦИЯ

**Procedures for
purchasing pharmaceuticals
and medical devices from domestic
manufacturers**

Procedure for conclusion of the Long-term Contract between domestic manufacturer (DM) and the Uniform Distributor for supply of pharmaceuticals and medical devices within the framework of GAFMC and Compulsory Social Health Insurance according to Chapter 20 of Rules 1729.



Inter-agency structure of the tender commission for conclusion of Long-term contracts for supply of pharmaceuticals and medical devices



Ministry of
Healthcare of the
Republic of Kazakhstan

[VISIT THE WEBSITE](#)



Ministry of Industry
and infrastructural development
of the Republic of Kazakhstan

[VISIT THE WEBSITE](#)



Ministry of National
Economy of the Republic
of Kazakhstan

[ПЕРЕХОД НА САЙТ](#)



National Center for
Expertise of Medicines and
Medical Devices of MH of RK

[VISIT THE WEBSITE](#)



«SK-Pharmaceuticals» LLP
(Uniform distributor)

[VISIT THE WEBSITE](#)



ATAMEKEN

The national chamber of
entrepreneurs of the Republic
of Kazakhstan "Atameken"

[VISIT THE WEBSITE](#)

Non-governmental
organizations

Evaluation criteria for applications of potential suppliers of Domestic Manufacturers when concluding long-Term Contracts for the supply of Pharmaceuticals and Medical Devices



Availability of financial resources (own and attracted)

1
point



Experience of pharmaceutical production in Kazakhstan for at least 5 years

3
point



Experience in pharmaceutical production outside Kazakhstan for at least 5 years

2
point



Availability of a land plot in ownership or lease (including trust management, temporary land use).

2 point
1 point



Manufacture of pharmaceuticals and medical devices entirely of Kazakhstan origin exclusively from products originating in the territory of the Republic of Kazakhstan.

3
point

Procedure for purchasing pharmaceuticals and medical devices from DM under the Long-Term Contract (LTC) as per Chapter 20 of the Rules 1729




Terms of concluding Supplementary to contract to LTC

- 1) inclusion of pharmaceuticals and medical devices in the list of a uniform distributor;
- 2) submission by customers of applications for pharmaceuticals and medical devices;
- 3) confirmation by the supplier of compliance with the requirements of Chapters 3 and 4 of Regulation 1729;
- 4) submission of a certificate of origin of goods for internal circulation " CT-KZ ", as well as a certificate for the production of pharmaceuticals in accordance with the requirements of GMP and/or production of medical devices in accordance with the requirements of international standard;
- 5) submission of the delivery schedule.

Grounds for termination of LTC

- 1) exceeding the investment project implementation period set out in these Regulations;
- 2) violation of obligations stipulated in the long-term contract of supply;
- 3) refusal of production and delivery before the beginning of delivery or refusal of delivery within two consecutive years from the date of beginning of delivery;
- 4) Violation of the investment project implementation schedule;
- 5) late submission of the semi-annual progress report on the investment project implementation, submission of which is stipulated in the long-term contract of supply;
- 6) Document of the authorized body on unproven clinical efficiency of the medicinal product.

The procedure for purchasing contract manufacturing from a Uniform Distributor for the supply of originals and medical devices as part of the GAFMC and Compulsory Social Health Insurance under Chapter 21-1 of Regulation 1729



Structure of the tender commission for conclusion of Long-term contracts with with the Customer of contract production for supply of pharmaceuticals and medical devices



Ministry of Healthcare of
the Republic of Kazakhstan

[ПЕРЕХОД НА САЙТ](#)



National Center for Expertise of
Medicines and Medical
Devices of MH of RK

[ПЕРЕХОД НА САЙТ](#)



«SK-Pharmaceuticals» LLP
(Uniform distributor)

[ПЕРЕХОД НА САЙТ](#)

Terms and conditions for conclusion of Long-term Contracts with the Customer of contract manufacturing operations



The manufacturer is a legal entity under the laws of a foreign country.



Manufacturer's right to manufacture and/or wholesale, retail sales of pharmaceuticals and medical devices



Contract manufacturing agreement with a manufacturer based in the Republic of Kazakhstan



Business plan, List of pharmaceuticals and medical devices planned for production, Copy of patent for original pharmaceuticals and medical devices

Stages in the conclusion of the Long Term Agreement with DM suppliers who have an medical devices manufacturing facility with a Uniform Distributor under Chapter 20 of Regulation 1729



Structure of the tender commission for conclusion of Long-term contracts with suppliers of Domestic Goods Manufacturers having production of Medical Devices requiring servicing



Ministry of Healthcare
of the Republic of
Kazakhstan

[VISIT THE WEBSITE](#)



National Center for
Expertise of Medicines and
Medical Devices of MH of RK

[VISIT THE WEBSITE](#)



«SK-Pharmaceuticals»LLP
(Uniform distributor)

[ПЕРЕХОД НА САЙТ](#)



ATAMEKEN

The national chamber of
entrepreneurs of
the Republic of Kazakhstan "Atameken"

[ПЕРЕХОД НА САЙТ](#)

Non-governmental organizations
(specialized associations in the
pharmaceutical or medical industries)

Evaluation criteria for applications from potential DM suppliers having production of medical devices requiring maintenance when entering into Long Term Contracts



A licence to manufacture medical devices that require service maintenance



Availability of a standardised certificate of origin of goods for internal circulation "CT-KZ".




Medical device production complies with the quality management system standard ISO 13485.




Availability of MI registration in Kazakhstan. Medical devices relating to measuring instruments are registered in the MI Register of the RK

STANDARD OF STATE SERVICE

"State registration, re-registration and amending the registration dossier of pharmaceuticals or Medical devices"



Procedure for drawing up lists of procuring entities and medical devices




Statutory and regulatory enactments

- Code of the Republic of Kazakhstan "On Public Health and the Healthcare System";
- The Law of the Republic of Kazakhstan "On Public Procurement";
- The Law of the Republic of Kazakhstan "On Compulsory Social Health Insurance";
- Resolution of the Government of the Republic of Kazakhstan dated October 30, 2009 № 1729 "On approval of the Rules for the organization and conduct of procurement of medicines and medical devices, pharmaceutical services;
- Resolution No. 515 of the Government of the Republic of Kazakhstan dated 8 July 2015 "On Approval of Rules for the Purchase of Storage and Transportation of Medicines and Medical Devices by a Uniform Distributor within the Guaranteed Volume of Free Medical Care and the Mandatory Social Health Insurance System";
- Resolution of the Government of the Republic of Kazakhstan No. 1781 of 7 November 2009 "On a single distributor within the guaranteed scope of free medical care and medical assistance in the compulsory social insurance system for the purchase of medicines, medical devices, services for storage and transportation of medicines, medical devices and conclusion of contracts, long-term contracts, as well as organization of the purchase of medical equipment";
- Decree No. 20 of the Minister of Health and Social Development of the Republic of Kazakhstan dated 18 January 2017 "On approval of forms of documents for participation in the purchase of medicines, preventive (immunobiological, diagnostic, disinfectant) drugs, medical devices and medical equipment, pharmaceutical services to provide a guaranteed amount of free medical care and medical assistance in the system of compulsory social health insurance";
- Decree of the Minister of Health of the Republic of Kazakhstan No. 931 dated 8 December 2017 "On approval of the Kazakhstan National Medicinal Form";
- Order of the Acting Minister of Health of the Republic of Kazakhstan dated 17 June 2020 No. ҚР ДСМ-68/2020 "On Amendments to the Order of the Acting Minister of Health of the Republic of Kazakhstan dated 19 April 2019 No. ҚР ДСМ-42 "On Approving the Rules for Regulation of Prices for Medicines";

Statutory and regulatory enactments

- Decree of the Minister of Health of the Republic of Kazakhstan dated 28 July 2020 No. ҚР СPM - 90/2020 "On approval of the list of drugs, medical devices within the guaranteed scope of free medical care and in the system of compulsory social health insurance, purchased from the Uniform Distributor for 2021";
- Decree of the Minister of Health of the Republic of Kazakhstan dated January 9, 2020 No. ҚР DSM-1/2020 "On Amendments to the Decree of the Minister of Health of the Republic of Kazakhstan dated August 29, 2017 No. 666 "On Approval of the List of Medicines and Medical Devices within the Guaranteed Volume of Free Medical Care, including Certain Categories of Citizens with Certain Diseases (Conditions) of Free and/or Preferential Medicines and Medical Devices at Outpatient Level".
- Decree No. 392 of the Minister of Health and Social Development of the Republic of Kazakhstan dated 27 May 2015 "On approval of good pharmaceutical practices".






СК-ФАРМАЦИЯ

INFORMATION AND ANALYTICAL UNIT OF SK-PHARMACEUTICALS


Structure of the Kazakhstan pharmaceutical market in the first half of 2020

Structure of pharmaceutical market in the first half of 2020

money terms




in physical term




Источник: IQVIA

Market structure in DM production for 2020



Volume of exports for the period from 2015 to 2020 (million KZT)




Country structure of total exports for the period 2015 - 2020.




Total government procurement from DM for 2020, share of TOP 10 manufacturers - 87.4%

Analysis of procurement under Long Term Contracts

Total purchase from DM for 2010-2020 - 312.4 billion KZT



DM share in medicine procurement in GAFMC, % of procurement volume in monetary terms



The increase in the share of domestic production of pharmaceuticals is due to the launch of new production facilities and modernization of existing facilities, as well as an increase in the range of products manufactured.

Conclusion of long-term contracts with DM in dynamics

For the entire period from 2009 to 2019:

- 1) 75 LTC has been concluded,
 - 2) 12 LTC has been terminated,
 - 3) there are 63 LTC with 32 DMs for 3,577 items.
- The forecast for 2025 is that the share of DM with the existing LTC will be approximately 45% in monetary terms of purchased units

Competition for 2020

- 1) 24 winners were determined for the supply of 292 pharmaceuticals and 1173 MI.
- 2) 88 Long-term contracts will be valid with 36 DM for the supply of 5,042 pharmaceuticals and medical devices (996 pharmaceuticals and 4,046 Medical devices) of which 40 Long-term contracts for pharmaceuticals and 48 Long-term Medical devices.

TOP 10 PRODUCERS IN KAZAKHSTAN 2020

No.	Producers	Volume in 2020, mln tg.	Depth of localisation (government content), %	Capacity of production, units/year*	Q-ty of positions in LTC	Share of exports in production volume, %
1	JSC "Nobel AFF"	15 786,1	87%	1 030 000 000	147 pharm-s	21,4
2	JSC "Chimphram"	15 267,2	53%	733 440 000	181 pharm-s	1,4
3	«KFK» LLP	4 731,8	65%	126 088	66 pharm-s	0
4	"Abdi Ibrakhim" LLP	3 738,6	91%	1 500 000 000	85 pharm-s	0
5	«Kelun-Kazpharm» LLP	2 755,0	66%	90 000 000	28 pharm-s	29,3
6	"Super-pharm" LLP	2 140,3	68%	32 000 000	319 med. devices	0
7	"EcoPharm International" LLP	2 081,0	75%	750 000 000	119 med. devices	0
8	"Dolce" LLP	2 043,0	83%	157 000 000	49 med. devices	0
9	«KazMedProm» LLP	1 679,2	70%	55 000 000	22 med. devices	0
10	"Nur-Mai Pharmacy" LLP	1 292,9	30%	6 000 000	42 pharm-s	0

The share of the TOP 10 in total purchases from DM for 2020 is 87.4%.
 JSC Nobel AFF and JSC Chimpharm account for 60% of the TOP-10.
 JSC Nobel AFF , Khimpharm JSC, Kelun-Kazpharm LLP - export oriented
 Abdi Ibrahim LLP, JSC Nobel AFF , Dolce LLP have more than 80% of the state content
 6 of the TOP 10 are producing pharmaceuticals, 4 of the TOP 10 are producing medical devices.

48% COVID-19 produced by DM
 10 million masks purchased from DM for retail in the amount of KZT 391.6 million
 Increase in COVID-19 (Rivaroxaban Nobel AFF, 40% cheaper than the original price)

** production capacity based on actual data from reports submitted by DM*



СК-ФАРМАЦИЯ

**LIST OF ITEMS ON THE SINGLE
DISTRIBUTOR LIST FOR 2021,
NOT DECLARED BY DOMESTIC
MANUFACTURERS**

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
	L-asparaginase****	lyophilisate to prepare a solution for intravenous and intramuscular administration 5000 IU	vial	14 484,71	268
	Abiratheron	tablets, 500 mg	tablet	15 633,81	40 860
Fabry disease	Adalimumab beta	lyophilizate for preparing a concentrate for preparing a solution for infusion 35 mg	vial	1 220 565,58	274
Other gangliosidosis, Fabry disease	Agalcidase alpha****	concentrate for preparing a solution for infusion 1 mg/ml, 3.5 ml	vial	642 381,27	131
Grohn's disease, ankylosing spondylitis, psoriasis	Adalimumab	solution for subcutaneous administration , 40 mg/ 0,4 ml	ampoule	142 550,09	918
	Adsorbed pertussis -diphtheria-tetanus vaccine containing cell - free	adsorbed cell -free pertussis -diphtheria -tetanus liquid vaccine, 1 dose	dosage	6 411,13	368 800
	Adsorbed diphtheria -tetanus toxoid with reduced content	diphtheria tetanus toxoid purified with reduced antigen content, liquid, suspension for injection	dosage	53,41	1 177 830
	Axitinib***	tablet, 1 mg	tablet	5 886,86	168
ascaris infection, enterobiasis, ancylostomiasis	Albendazole	tablet 200 mg	tablet	758,53	42 306
	Amisulpride	tablet, 200 mg	tablet	250,25	59 105
	Amisulpride	tablet, 400 mg	tablet	301,97	34 430
Rye, Chronic Urinary System Infections, Acute Respiratory Infections of the Lower Respiratory Tract, Gastritis and Duodenitis, Gastric and 12 duodenal ulcer, Outpatient Pneumonia, Pneumonia, Cholecystitis/Cholangitis, Scarlatina.	Amoxicillin	tablet/capsule 500 mg	tablet/capsule	52,62	667 127
Rye, Gastric and 12 duodenal ulcer, Acute respiratory infections of the lower respiratory tract, Cholecystitis/Cholangitis, Outpatient pneumonia, Chronic Urinary System Infections, Scarlatina, Pneumonia, Gastritis and Duodenitis.	Amoxicillin	tablet/capsule 250 mg	tablet/capsule	24,41	296 203
Lyme Disease, Sinusitis / Almond and Adenoid Disease, Urogenital System Infections, Chronic Urinary System Infections, Acute Respiratory Infections of the lower respiratory tract, Acute/chronic purulent otitis, Acute/chronic sinusitis, skin and subcutaneous tissue infections, urinary tract infections/ Urethritis cystitis and urethral syndrome, hydradenitis purulent, inflammatory diseases of the hearing organs, tuberculosis, acute/chronic tubulointerstitial nephritis.	Amoxicillin-clavulanic acid ****	tablet, film coated 1000mg	tablet	147,15	514 139
Sinusitis / almond and adenoid diseases, inflammatory diseases of the hearing organs, acute/chronic purulent otitis, acute/chronic tubulointerstitial nephritis, tuberculosis, Urinary tract infection/ Urethral cystitis and urethral syndrome, Lyme disease, genitourinary tract infections, acute respiratory infections of the lower respiratory tract, acute/chronic sinusitis, skin and subcutaneous tissue infections, Hydradenitis purulent.	Amoxicillin sodium, potassium clavulanate ****	oral suspension powder 200mg/28.5 mg/5ml 70ml	vial	1 321,77	37 857
Gastritis and duodenitis, Acute respiratory infections of the lower respiratory tract, Rose, Cholecystitis/Cholangitis, Gastric and 12 duodenal ulcer, Pneumonia, Chronic infections of the genitourinary system, Scarlatina, Outpatient pneumonia.	Amoxicillin****	tablet/capsule 1000 mg	tablet/capsule	85,40	936 660

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Cholecystitis/Cholangitis, Pneumonia extrahospital, Scarlatina, Gastritis and duodenitis, Rose, Pneumonia, Acute Respiratory Infections of the lower respiratory tract, Stomach and 12 duodenal ulcer.	Amoxicillin* * *	powder/granules for the preparation of suspension for ingestion 250 mg	vial	947,77	79 226
Acute respiratory infections of the lower respiratory tract, sinusitis / almond and adenoid diseases, acute/chronic sinusitis, acute/chronic.	Amoxicillin+ clavulanic acid* * *	100 ml oral suspension powder 156.25 mg/5 ml or 156 mg/5 ml	vial	1 180,97	49 593
Tubulointerstitial nephritis, Acute/chronic purulent otitis, Skin and subcutaneous tissue infections, Inflammatory hearing organ diseases, Urogenital infections, Tuberculosis, Urinary tract infection/ Urethral cystitis and cystitis, Hydradenitis purulent, Lyme disease	Amoxicillin+ clavulanic acid* * *	457 mg/5 ml oral suspension powder	vial	1 094,85	37 478
Hydradenitis purulent, acute/chronic tubulointerstitial nephritis, acute respiratory infections of the lower respiratory tract, tuberculosis, acute/chronic sinusitis, inflammatory hearing disease, Lyme disease, Urogenital tract infections, skin and subcutaneous tissue infections, sinusitis / tonsil and adenoid diseases, urinary tract infections / Urethritis cystitis and urethral syndrome, acute/chronic purulent medium otitis.	Amoxicillin+ clavulanic acid* * *	injectable solution powder, 600 mg	vial	329,03	402 171
Infectious endocarditis (acute/subacute)	Ampicillin****	500 mg injection powder	vial	340,56	1 237 501
	Amphotericin B*****	Powder for cooking concentrate for the preparation of variance for infusions 50 mg/Concentrate (lipid complex) for intravenous solution, 50 mg/10 ml	vial	40 082,60	1 190
Hereditary deficits in blood -clotting factors	Anti-inhibitory coagulant complex****	liophilisate for the preparation of a solution for infusions 1000 Units	vial	334 612,32	3 655
Hereditary deficits in blood -clotting factors	Anti-inhibitory coagulant complex	liophilisate for the preparation of a solution for infusions 500 Units	vial	161 078,66	1 217
	Anti-slavery vaccine, concentrated	vaccine anti -rabic cultured concentrated inactivated, freezeophilized in vials or vials at 1 graft dose. A solvent is attached to each vial or vial of the vaccine.	vial/ ampoule	5 096,68	273 500
	Anti-slavery immunoglobulin (serum)	transparent or weakly opalescing liquid colorless or faintly yellow coloring. Release form - vials or vials of 5 or 10 ml	l	754 492,00	246
	Aprotinin	solution for infusions 10,000 KIE/ml, 10 ml	ampoule	1 387,68	239 110
	Ascorbic acid	drops for 100 mg/ml, 30 ml	vial	441,93	60 046
Muscular Dystrophy, Duchenne Muscular Dystrophy	Ataluren	250 mg oral suspension pellets	vial	103 396,87	14 889
Muscular Dystrophy, Duchenne Muscular Dystrophy	Ataluren	125 mg oral suspension pellets	vial	51 836,94	8 849
Muscular Dystrophy, Duchenne Muscular Dystrophy	Ataluren	1000 mg oral suspension pellets	vial	410 442,65	0
	Atosiban	concentrate for preparation of solution for infusions 7.5 mg / ml 5 ml	vial	37 758,34	332
	Atosiban****	solution for injection 7.5 mg / ml 0.9 ml	vial	12 009,59	139
Infections caused by herpes/herpes virus	Acyclovir****	cream/ointment 5g	tube	566,30	14 719
Oncological diseases	BCC Bacteria ****	slurp powder for intra -traumatic introduction in solvent kit	vial	39 291,27	2 770
Bronchial asthma	Beclomethasone	spray dosed for inhalation 250 micrograms/dosage, 200 doses, activated by inhalation	cartridge	5 524,61	28 334
Bronchial asthma	Beclomethasone	100 micrograms/dosage aerosol, 200 doses, breath -activated	cartridge	4 688,41	14 993
	Bendamustin****	powder for cooking concentrate for cooking solution for infusions 100 mg	vial	184 704,03	1 212
	Benzylpenicillin****	powder for preparation of solution for injection 1,000,000 UNITS	vial	32,10	726 561
Psoriasis, Dermatitis, Nest Alopecia	Betamethason	Cream 0.05% 30g	tube	1 332,93	5 004
Дерматиты, Псориаз, Гнездная алопеция, Гнездная алопеция	Betamethason	крем 0,05% 15 г	tube	978,16	3 269

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
	Betamethason ***	injection suspension, 1 ml	Syringe/ ampoule	871,25	14 180
Crack and fistula of the anus and rectum, patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage decompensation of cardiac, pulmonary, liver, renal failure, constipation	Bisacodil****	rectal suppository 10mg	Suppository	21,61	91 766
Benign breast dysplasia, hormonally active pituitary tumors . Acromegaly	Bromocriptine ****	tablet, 2,5 mg	tablet	69,90	189 443
Bronchial asthma	Budesonide	inhalation suspension dosed 0.25 mg/ml 2 ml	ampoule	569,79	1 161 322
Bronchial asthma	Budesonide	inhalation suspension dosed 0.5 mg/ml 2 ml	ampoule	572,13	1 095 937
Chronic obstructive pulmonary disease, bronchial asthma	Budesonide q Formoterol fumarata digidrat	Inhalation powder, 160/4.5 micrograms, 120 doses	Inhaler	12 263,51	102 409
Bronchial Asthma, Chronic Obstructive Pulmonary Disease	Budesonide q Formoterol fumarata digidrat	Inhalation powder, 160/4.5 micrograms, 60 doses	Inhaler	7 278,37	50 432
Chronic obstructive pulmonary disease, bronchial asthma	Budesonide q Formoterol fumarata digidrat****	Inhalation powder, 320/9 micrograms, 60 doses	Inhaler	15 088,81	64 432
Bronchial Asthma, Chronic Obstructive Pulmonary Disease	Budesonid, formoterol fumarat digidrat	inhaled powder dosed 80/4.5mcg/dosage 120dise	Inhaler	15 656,34	36 151
Bronchial Asthma, Chronic Obstructive Pulmonary Disease	Budesonid, formoterol fumarat digidrat	inhaled powder dosed 80/4.5mcg/dosage 60dise	Inhaler	8 880,29	10 885
	Bupiracain	0.5% injection solution	ampoule	120,55	105 925
	Vaccine diphtheria -tetanus-cellless whooping cough, combined with the recombinant hepatitis B vaccine, inactivated polio vaccine and b -type haemophilic haemophilic vaccine	combined, as part of vaccines: diphtheria -tetanus with cell -free whooping cough, viral hepatitis B, polio inactivated, haemophilic infection type B, at 1 dose	dosage	14 454,16	657 350
	Diphtheria-tetanus-cell-free whooping vaccine combined with inactivated polio vaccine and b -type haemophilic haemophilic vaccine	combined, as part of vaccines: diphtheria -tetanus with cell -free whooping cough, polio inactivated, haemophilic infection type B, at 1 dose.	dosage	6 896,69	708 900
	Influenza vaccine	inactivated vaccine, the composition of strains must be matched WHO recommendations, taking into account the circulation of influenza viruses in the upcoming epidemiological season. Injection suspension in syringe 1 dosage/0.5 ml	dosage/Syringe	986,19	2 059 922
	Vaccine against typhoid	vaccine enriched with V1 -antigen is produced in vials or vials in 1; 5 or 10 doses	dosage	1 157,44	15 515
	Vaccine against tick -borne encephalitis, concentrated, inactivated	cultural, purified, concentrated, inactivated for intramuscular administration, contains inactivated antigen of tick -borne encephalitis virus, in vials or vials	dosage	2 393,49	51 330
	Vaccine against measles, rubella and mumps	a freeze-dried vaccine that consists of live attenuated strains of measles, mumps and rubella viruses. Release form - vial at 1 dose complete with solvent. Vaccine production certified by WHO	dosage	1 873,46	684 550
	Vaccine against pneumococcal disease	polysachide conjugated inactivated liquid vaccine containing 13 pneumocococcus serotypes. The form of release - 1 dose. Vaccine production must be certified by WHO	Syringe/ dosage	10 434,00	954 708
	Vaccine against pneumococcal disease	Polysaccharide conjunctivated inactivated liquid vaccine containing 10 pneumococcus serotypes, suspension for intramuscular administration 0.5 ml/dosage. Vaccine production should be WHO-certified	Syringe/ dosage	7 213,82	0
	Polio vaccine, oral	live oral, contains attenuated strains of polio viruses immunological types - 1.3 (bivalent). Release form - vial by 10; 20 doses, complete with drip or in a plastic vial pipett	dosage	82,12	458 500

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
	Tuberculosis vaccine	live, lipophilically dried. Form release -ampoules or vial at 20 doses for intracutaneous administration. Vaccine production must be certified by WHO	dosage	76,81	1 571 300
Epilepsy, Cerebral Palsy	Valproic acid	Delayed release capsules , 300 mg	capsule	38,42	811 856
Cerebral palsy, Epilepsy	Valproic acid	oral drops by 100 ml	vial	2 087,24	22 880
Patients with prosthetic heart valves, arrhythmias	Warfarin	tablet 5mr	tablet	17,86	357 456
	Vedolizumab	Powder for the preparation of concentrate for the preparation of the solution for infusions 300 mg	vial	702 247,20	334
Arrhythmia	Verapamil	tablet, 40mr	tablet	22,93	546 840
	Vilanterol and umoclinydia bromide	inhaled powder dosed , 22 mcg/55 mcg	Container	15 451,00	30
	Vilanterol and fluticazone furoate	inhaled powder dosed , 92 mcg/22 mcg	Container	12 172,51	60
Diabetes	Wildagliptine	tablet 50 mg	tablet	166,14	2 523 997
	Galantamine	injection solution , 2,5 mg/ml	ampoule	118,23	16 580
	Galantamine	injection solution , 10 mg/ml	ampoule	431,74	12 200
	Galantamine	injection solution , 5 mg/ml	ampoule	220,94	11 680
Mental illness	Haloperidol	tablet 5mr	tablet	11,55	3 121 284
	Haloperidol	injection solution , 5 mg/ml, 1 ml	ampoule	59,60	289 275
Mental illness	Haloperidol	oily solution for injections , 50mr/ ml 1 ml	ampoule	429,57	103 709
	Halotan	liquid for inhalation anesthesia, 250 ml	vial	10 273,55	813
	Hydrocortisone	suspension (microcrystal) for injections 2,5%, 5 ml	vial	985,24	21 395
Psoriasis, Erythema multiform	Hydrocortisone	Ointment 1%	tube	200,86	12 946
	Hydrochlorothiazide	tablet, 100 mg	tablet	50,07	43 315
Diabetes	Glucagon	lyophilisate for the preparation of an injection solution complete with solvent 1 mg	vial	5 640,58	4 568
	Glucose	injection solution 40%, 10 ml	ampoule	31,41	451 668
Gastroenteritis and colitis of infectious origin	Glucose waterless, sodium chloride, potassium chloride, sodium citrate ****	powder to make a solution for ingestion 18,9 r	Package	157,92	245 523
Gastroenteritis and colitis of infectious origin	Glucose waterless, sodium chloride, potassium chloride, sodium citrate ****	powder to make a solution for ingestion 10,7 r	Package	166,18	53 243
Cancer	Gozerelin	extended-action implant for subcutaneous administration 3,6 mg	syringe applicator	47 198,49	3 529
Cancer	Gozerelin	implant for subcutaneous administration of prolonged action , 10,8 mg	syringe applicator	132 549,76	3 420
	Sponge hemostatic	including, fibrinogen, thrombin, size 4,8*4,8	pse	33 063,67	5 637
	Sponge hemostatic	including, fibrinogen, thrombin, size 9,5*4,8	pse	62 478,72	4 779
	Sponge hemostatic	including, fibrinogen, thrombin, size 2.5*3.0	pse	15 423,95	3 569
	Sponge hemostatic ****	Size 25*30*05	pse	4 728,86	3 436
	Sponge hemostatic ****	Size 48*48*05	pse	10 525,44	2 483
	Sponge hemostatic ****	Size 95*48*05	pse	19 137,90	1 142
	Daratumab****	concentrate for infusions, 400mg/20 ml, 20 ml	vial	813 531,74	833
	Daratumab****	concentrate for infusions, 100 mg / 5 ml, 5 ml	vial	206 464,57	525
HIV infection	Darunavir	tablet, 800 mg, with each unit of the drug additionally provided 1 tablet/capsule Ritonavir 100 mg	tablet	3 681,40	0
	Degarelix	freeze-dried powder to prepare an injection solution complete with solvent, 80 mg	vial	49 734,39	582
	Degarelix	freeze-dried powder to prepare an injection solution complete with solvent, 120 mg	vial	49 669,52	160
	Dexamethasone	Injection solution 4 mg/ml, 1 ml	ampoule	41,85	3 756 200

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal insufficiency, malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasia syndromes	Dexamethasone	tablet 0,5mg	tablet	27,19	129 530
Iridocyclitis	Dexamethasone	Eye drops , 1 mg/ml, 10 ml №1	vial	167,64	22 962
	Denozumab ****	subcutaneous solution, 60 mg/ml	Syringe	66 977,61	1 740
Diabetes insipidus	Desmopressin	oral 120mcg lyophilisate	oral lyophilisate	541,36	1 191 047
Diabetes insipidus	Desmopressin	oral 60mcg lyophilisate	oral lyophilisate	265,01	262 957
Diabetes insipidus	Desmopressin	oral lyophilisate 240mcg	oral lyophilisate	1 105,34	141 619
Malignant tumors of lymphoid, blood-forming and related tissues, including myelodisplasia syndromes, hematological diseases, including aplastic anemia	Deferazirox	Film-covered tablets, 180 mg	tablet	5 188,84	450
	Decitabin	iophilisate for cooking solution for infusions, 50 mg	vial	426 548,79	439
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal Failure	Diazepam (U)	solution for intramuscular and intravenous application 5mg/ml 2ml	ampoule	95,87	575 341
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal insufficiency , Cerebral Palsy, Mental Illness	Diazepam (U)	tablet 5mg	tablet	10,48	277 584
Chronic heart failure, arrhythmia	Digoxin****	tablet, 0,25 mg	tablet	2,80	2 197 392
HIV infection	Dolutegravir****	tablet, 25 mg	tablet	1 380,40	18 030
HIV infection	Dolutegravir****	tablet, 10 mg	tablet	1 285,20	13 980
Diabetes	Duluglutide****	Solution for subcutaneous administration 1.5 mg/0.5 ml	pen injection	10 684,32	89 414
Diabetes	Duluglutide****	Solution for subcutaneous administration 0.75 mg/0.5 ml	pen injection	10 943,72	18 165
Diabetes	Needles to pen injection ****	No more than 0.33 mm x 5 mm in diameter	psc	22,47	8 209 110
Mukopolisacharidosis	Idursulfaza beta	concentrate for infusions, 2 mg/ml, 3 ml	vial	1 132 290,83	52
Tuberculosis	Isoniazid	Injection solution 10%, 5 ml	ampoule	69,71	23 765
Tuberculosis	Isoniazid****	syrup, 100 mg/5 ml 200 ml	vial	7 224,91	5 486
Ischemic heart disease	Isosorbida dinitrate	aerosol/spray 1.25 mg/1 dosage, 300 doses 15 ml	vial	1 694,06	176 875
Acne sickness	Isotretinoin	capsule 16 mg	capsule	474,45	540
Acne sickness	Isotretinoin	capsule 8 mg	capsule	273,58	215
	Isofluran	liquid for inhalation anesthesia, 250 ml	vial	29 793,85	4 364
	Isofluran	liquid for inhalation anesthesia, 100 ml	vial	16 131,34	1 439
Primary pulmonary hypertension	Iloprost ****	solution for inhalation 10 micrograms/ml, 2 ml	ampoule	5 938,50	130 284

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
	Immunoglobulin anti -cymocytic****	lyophilisate for cooking solution for infusions, 25 mg	vial	56 438,38	430
	Immunoglobulin against tick -borne encephalitis ****	prepared from serum of horses hyperimmunized by tick -borne encephalitis virus or from serum donors	l	7 285 410,00	53
	Human immunoglobulin is normal	10% infusion solution, 100 ml	vial	240 222,26	2 956
	Inactivated hepatitis A vaccine. Vaccine production	injection suspension in 1 dosage/0.5 ml vial/syringe	vial/ampoule	5 498,80	699 003
Chronic obstructive pulmonary disease	Indacaterol ****	150mcg inhaled powder	capsule	392,27	905 700
Chronic obstructive pulmonary disease	Indacaterol ****	300mcg inhaled powder	capsule	377,81	435 172
Diabetes	Insulin aspart	100 ed/ml solution in 3 ml cartridges complete with syringe pens for 50 cartridges 1 syringe pen with 1 ED increment. Supplies are not available in cartridges, but in already fueled injection pens, in this case Syringe - insulin pens are not needed	cartridge/ injection pen	2 862,33	656 123
Diabetes	Insulin aspart	100 ed/ml solution in 3 ml cartridges complete with injection pens for 50 cartridges 1 injection pen with 0.5 ED increment	cartridge	2 862,33	86 720
Diabetes	Insulin aspart two-phase in combination with medium duration insulin (a mixture of insulin analogues short and medium duration)	100-ml suspension in 3 ml cartridges complete with syringe pens for 50 cartridges 1 syringe pen with 1 ED increment. Possible supplies not in cartridges, but in already filled syringe - pens, in this case a syringe - pens to insulin are not needed	cartridge/ injection pen	2 902,49	527 965
Diabetes	Insulin gluluzine****	solution 100 ed/ml 10.0 ml	vial	7 694,37	5 492
Diabetes	Insulin two -phase human genetic engineering (30/70)	100-ml suspension in 3 ml cartridges complete with syringe pens for 50 cartridges 1 syringe pen with 1 ED increment. Possible supplies not in cartridges, but in already filled syringe - pens, in this case a syringe - pens to insulin are not needed	cartridge/ injection pen	1 020,86	172 231
Diabetes	Insulin two -phase human genetic engineering (30/70)****	suspension 100 units/ml in vials, 10 ml	vial	1 288,97	3 749
	Insulin degludek ****	Injection solution 100 ED/ml, 3 ml, pre -filled injection pens	injection pen	5 011,70	1 550
Diabetes	Insulin lyspro	100 ed/ml solution in 3 ml cartridges complete with syringe pens for 50 cartridges 1 syringe pen with 1 ED increment. Supplies are not available in cartridges, but in already fueled Syringe - pens, in this case Syringe - insulin pens are not needed	cartridge/ injection pen	2 703,44	379 944
Diabetes	Insulin lyspro	100 ed/ml solution in 3 ml cartridges complete with syringe pens for 50 cartridges 1 syringe pen with 0.5 units increment	cartridge	2 703,44	86 575
Diabetes	Insulin lyspro two-phase in combination with medium duration insulin (a mixture of insulin analogues short and medium 50/50)	100 ed/ml solution/suspension in 3 ml cartridges complete with syringe handles for 50 cartridges 1 syringe pen with 1 ED increment. Supplies are not available in cartridges, but in already refilled syringe pens, in which case syringe pens to insulin are not needed	cartridge/ injection pen	3 045,89	208 977
Diabetes	Insulin lyspro****	Injection solution 100 IU/ml, 10 ml	vial	7 529,86	7 352
Diabetes		The length of the cannula is 6 mm	kit	4 077,77	172 424
Diabetes		Length of cannula 9 mm	kit	4 077,77	16 267
	Irinotecan ****	300 mg/15 ml infusion concentrate	vial	42 851,95	1 315
	Ifosfamid***	powder for intravenous injection, 500 mg	vial	6 203,68	3 620
	Idfsfami****	injectable solution powder, 1000 mg	vial	11 596,95	1 604
	Ifosfamid****	injectable solution powder, 2,000 mg	vial	17 215,48	600
Diabetes	Canagliflozin	tablet, 300 mg	tablet	440,18	3 230 912
Diabetes	Kangagliflozin ****	tablet, 100 mg	tablet	425,58	2 873 742
	Carbetocin	Injection solution 100 mcg/ml, 1 ml	ampoule	11 579,78	23 807
	Carboplatin ****	Concentrate for infusions 10mg/ml 45 ml in vial /, Injection solution 450mg/45ml by 45 ml in vial	vial	15 554,57	5 120

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
	cartridge Xpert® MTB/RIF 50 tests IVD-FIND ****	Mycobacterium tuberculosis test and its resistance to rifampicin in macrota samples No. 50	package	246 013,26	1 365
	Kvetiapin	tablet, 100 mg	tablet	63,77	4 740
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal failure	Ketoprofen	capsule, 150 mg	capsule	70,28	474 306
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal failure	Ketoprofen ****	суппозиторий 100мг	suppository	101,58	89 184
	Cladribin****	Injection solution 1 mg/ml, 10 ml	vial	35 614,32	50
	Clarithromycin	freeze-dried powder for the preparation of a solution for infusions , 500 mg	vial	3 904,64	22 508
Mental illness	Clozapine	tablet 25 mg	tablet	10,37	5 792 105
Mental illness	Clozapine	tablet 100 mg	tablet	32,12	1 370 441
Mycoses	Clotrimazole	ointment/cream 1%	tube	268,13	8 086
Cancer	Kobemetinib****	Tablets 20 mg	tablet	34 505,42	25 241
Rickets	Kolecalziferol****	drops for ingestion 2800 IU/ml, 15 ml	vial	375,72	127 411
Cystic fibrosis (Cystic fibrosis)	Sodium colistimete****	powder for preparation of an injection solution or infusions 1 000 000 Units	vial	5 086,63	28 359
	Complex of amino acids ****	infusion emulsion containing a mixture of olive and soy oils at a ratio of 80:20, solution of amino acids with electrolytes, solution of dextrose, with a total calorie content of 1800 kcal 1,500 ml three - section container	container	14 157,87	10 909
	Complex of amino acids ****	infusion emulsion containing a mixture of olive and soy oils at a ratio of 80:20, solution of amino acids with electrolytes, solution of dextrose, with a total calorie content of 910 kcal 1,500 ml three - section container	container	11 328,46	5 468
	Complex botulinum toxin type a - hemagglutinin	500 ED lyophilisate for the preparation of the solution for intramuscular and subcutaneous administration	vial	79 879,80	2 356
	kit of products for gynecological examination disposable sterile	1. Cuzco Mirror, M 2 sizes. Gloves textured latex size: M - 1 pair, 3. Cytoszt out - 1 piece, 4. cloth lining 70x40 - 1 pc.	kit	890,54	36 900
	kit of products for gynecological examination disposable sterile	1. Cuzco Mirror, size S 2. The gloves are textured latex size: M - 1 pair 3. The cytosst - 1 piece 4. The napkin lining 70 X40 - 1 piece.	kit	890,54	19 452
	kit of products for gynecological examination disposable sterile	1. Cuzco Mirror, L 2 sizes. Gloves textured latex size: M - 1 pair, 3. Cytoszt out - 1 piece, 4. cloth lining 70x40 - 1 pc.	kit	890,54	11 720
HIV infection	Lamivudin - Abacavir q Dolutegravir ****	tablet, 300 mg/600 mg/50 mg	tablet	2 431,67	605 640
Epilepsy	Lamotrigine	tablet chewy 5mg	tablet	23,40	35 375
Hormonally active pituitary tumors. Acromegaly	Lanreotide****	Injection solution of 90 mg prolonged release	Syringe	461 796,98	49
Glaucoma	Latanoprost	eye drops 0.005%, 2.5 ml	vial	1 825,54	45 940
Epilepsy	Levetiracetam****	Oral solution, 100 mg/ml 300 ml	vial	11 783,98	9 064
	levomepromazine****	Injection solution 25 mg/ml	ampoule	158,96	108 150
Hypothyroidism/Hyperthyroidism/Hyoparathyroidism	Levotiroxin	tablet 100 mcg	tablet	8,12	11 065 781
Hypothyroidism/Hyperthyroidism/Hyoparathyroidism	Levotiroxin	tablet 75mkr	tablet	9,46	5 165 331
Hypothyroidism/Hyperthyroidism/Hyoparathyroidism	Levotiroxin	tablet 25mkr	tablet	7,22	2 948 983
Hypothyroidism/Hyperthyroidism/Hyoparathyroidism	Levotiroxin	tablet 150mkr	tablet	11,63	1 278 908

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Hypothyroidism/Hyperthyroidism/Hypoparathyroidism	Levotiroxin	tablet 125 mcg	tablet	9,55	1 200 491
Hereditary deficits of blood clotting factors	Drug clotting factors, blood VIII plasma without indications of treatment	Lyophilisate for the preparation of the solution	IU	56,40	8 452 215
Hereditary deficits of blood clotting factors	Drug clotting factors VIII plasma without indications of treatment Willebrand's disease with a restriction of use in young children (up to 12 years)*****	Lyophilisate for the preparation of the solution	IU	68,48	2 584 920
Hereditary deficits of blood clotting factors	Drug clotting factors, blood VIII plasma with indication of treatment Willebrand's disease with limited use	Lyophilisate for the preparation of the solution	IU	63,09	91 802 420
Hereditary deficits of blood clotting factors	Drug clotting factors, blood VIII plasma with an indication of the treatment of Willebrand's disease, without age	Lyophilisate for the preparation of the solution	IU	56,40	381 120
Hereditary deficits of blood clotting factors	Blood clotting factor drug VIII plasma, for children with inhibitory form of hemophilia A	Lyophilisate for the preparation of an intravenous solution in vial complete with solvent and injection kit, underwent double viral inactivation, including solvent -de-energy method, without content of albumin, sucrose and polyethylene glycol, with the ability to store at temperatures of up to 25oC for the duration of the term, including for the treatment of inhibitory form of hemophilia by induction of the immune Tolerance	IU	74,42	13 235 000
Rheumatoid arthritis, Psoriatic arthropathy	Lidocaine ****	tablet 20 mg	tablet	266,75	479 069
	Lidocaine	аэрозоль 10%, 38 ml or gram	vial	2 451,54	12 857
Diabetes	Lixysenatide****	Injection solution 0,1 mg/ml, 3 ml	injection pen	15 279,04	9 283
Diabetes	Lixysenatide****	Injection solution 0,05 mg/ml, 3 ml	injection pen	15 147,24	5 934
	Macrogol 3350 sodium sulfate waterless Potassium chloride	powder to make a solution for ingestion	packet	1 967,26	8 920
	Melfalan****	lyophilisi powder-rushed for the preparation of an injection solution 50 mg	vial	69 818,51	135
Malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasia syndromes	Mercaptopurin ****	tablet 50 mg	tablet	50,88	165 768
Ulcerative colitis, Crohn's disease	Mesalazin	tablets covered with intestinal soluble shell, with prolonged release, 1.2 g	tablet	397,24	288 087
Crohn's disease, ulcerative colitis	Mesalazin****	rectal suppository, 1g	psc	680,13	604 073
Ulcerative colitis, Crohn's disease	Mesalazin****	pellets with prolonged release, 2g	packet	573,15	493 246
Crohn's disease, ulcerative colitis	Mesalazin****	tablet, 400 mg	tablet	125,82	111 020
Ulcerative colitis, Crohn's disease	Mesalazin****	rectal suspension 1 g/100 ml, 1 g	vial	1 464,66	12 436
	Mesna****	solution for intravenous injection in vials 400 mg/4 ml	ampoule	825,78	21 090
Rheumatoid arthritis, Progressive Glomerular Diseases, Dermati, Systemic Lupus Erythema, Dermatopolisitis, Bechet's Disease, Hive and Erythema, Angioeurotic Swelling, Post -Transplant Diseases, Juvenile Arthritis, Psoriatic Arthropathy	Methylprednisolone ****	tablet, 16 mg	tablet	151,96	344 114
Rheumatoid arthritis	Methylprednisolone ****	freeze-dried powder for the preparation of an injection solution 250 mg	vial	1 931,50	48 035
Chronic kidney disease with renal anemia	Metoxy polyethylene glycol -epoethine beta****	50mcg/0.3ml intravenous and subcutaneous injection solution	syringe tube	38 557,05	2 674

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Rheumatoid arthritis, malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasia syndromes, Psoriatic arthropathy, Psoriasis, Juvenile arthritis, ulcerative colitis, Crohn's disease, systemic sclerosis (systemic scleroderma), Psoriatic arthropathy, knot polyarteritis and related conditions; Other necrotizing vasculopathy, knot polyarteritis and related conditions; Other necrotizing vasculopathy, Dermatopolisitis , Psoriasis, Systemic Sclerosis (systemic scleroderma)	Methotrexate	Injection solution 1000 mg	vial	22 881,44	3 213
Ulcerative colitis, Rheumatoid arthritis, juvenile arthritis, psoriatic arthropathy, Psoriasis, Systemic Sclerosis (systemic scleroderma), Crohn's disease, malignant tumors of lymphoid, blood-forming and related tissues, including myelo-disergic syndromes, dermatopolimiyositis , Systemic Sclerosis (systemic scleroderma), node polyarteritis and related conditions; Other necrotizing vasculopathy	Methotrexate ****	Injection solution , 50 mg/ml, 15 mg/0,3 ml	Syringe/injection pen	5 790,83	388 651
Rheumatoid arthritis, Psoriasis, Systemic Sclerosis (systemic scleroderma), juvenile arthritis, Psoriatic arthropathy, Psoriasis, Psoriatic arthropathy, uzul polyarteritis and related conditions; Other necrotizing vasculopathy, Dermatopolimiyositis , Crohn's disease, systemic sclerosis (systemic scleroderma), node polyarteritis and related conditions; Other necrotizing vasculopathy, Malignant lymphoid, blood -forming and related tissues, including myelodisplastic syndromes, ulcerative colitis	Methotrexate****	Injection solution , 50 mg/ml, 10 mg/0,2 ml	Syringe/injection pen	5 790,83	146 449
Crohn's disease, Rheumatoid arthritis, psoriatic arthropathy, Psoriasis, Ulcerative colitis, Systemic sclerosis (systemic scleroderma), Psoriatic arthropathy, knot polyarteritis and related conditions; Other necrotizing vasculopathy, malignant lymphoid tumors, blood-creating and related tissues, including myelo-discred syndromes, knot polyarteritis and related conditions; Other necrotizing vasculopathy, Systemic sclerosis (systemic scleroderma), Juvenile Arthritis, Psoriasis, Dermatopolisitis	Methotrexate****	Injection solution , 50 mg/ml, 12,5 mg/0,25 ml	Syringe/injection pen	5 595,94	98 466
Malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasia syndromes, Juvenile arthritis, ulcerative colitis, Crohn's disease, systemic sclerosis (systemic scleroderma), knot polyarteritis and related conditions; Psoriatic arthropathy, Psoriasis, Dermatopolimiyositis , Rheumatoid arthritis, uzul polyarteritis and related conditions; Other necrotizing vasculopathy	Methotrexate****	Injection solution , 50 mg/ml, 20 mg/0,4 ml	Syringe/injection pen	5 790,83	70 752
Crohn's disease, malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasia syndromes, knot polyarteritis and related conditions; Other necrotizing vasculopathy, Ulcerative colitis, Psoriatic arthropathy, knot polyarteritis and related conditions; Other necrotizing vasculopathy, Psoriasis, Dermatopolimiyositis , Juvenile Arthritis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis (Systemic Scleroderma), Psoriatic Arthropathy, Systemic Sclerosis (Systemic Scleroderma)	Methotrexate****	Injection solution , 50 mg/ml, 17,5 mg/0,35 ml	Syringe/injection pen	5 790,83	37 340

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasia syndromes, systemic sclerosis (systemic scleroderma), Psoriasis, ulcerative colitis, psoriatic arthropathy, Juvenal arthritis, Crohn's disease, Uzel polyarteritis and related conditions; Other necrotizing vasculopathy, rheumatoid arthritis, dermatopolisitis	Methotrexate ****	Injection solution , 50 mg/ml, 7,5 mg/0,15 ml	Syringe/injection pen	5 389,37	23 522
Crohn's disease, Psoriasis, Juvenile Arthritis, Systemic Sclerosis (Systemic Sclerosis), Malignant Tumors of Lymphoid, Blood -Forming and Related Tissue, Including Myelo-Disclatal Syndromes, Dermatopolimiyositis , Psoriasis, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthropody , Other necrotizing vasculopathy, Psoriatic arthropathy, knot polyarteritis and related conditions; Other necrotizing vasculopathy, Systemic Sclerosis (systemic scleroderma)	Methotrexate ****	Injection solution , 50 mg/ml, 25 mg/0,50 ml	Syringe/injection pen	5 790,83	1 992
Systemic sclerosis (systemic scleroderma), node polyarteritis and related conditions; Other necrotizing vasculopathy, Psoriasis, Dermatolymyositis , Crohn's disease, Psoriatic arthropathy, juvenile arthritis, malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasia syndromes, ulcerative colitis, rheumatoid arthritis, systemic sclerosis (systemic scleroderma), psoriasis, uedic polyarteritis and related conditions; Other necrotizing vasculopathy, Psoriatic arthropathy	Methotrexate ****	Injection solution , 50 mg/ml, 30 mg/0,60 ml	Syringe/injection pen	5 790,83	654
Crohn's disease, rheumatoid arthritis, malignant tumors of lymphoid, blood -forming and related tissues, including myelo-discaplation syndromes, Psoriatic arthropathy, knot polyarteritis and related conditions; Other necrotizing vasculopathy, Juvenile arthritis, Psoriatic arthropathy, Psoriasis, Systemic Sclerosis (systemic scleroderma), ulcerative colitis, dermatopolisitis	Methotrexate ****	Injection solution , 50 mg/ml, 22,5 mg/0,45 ml	Syringe/injection pen	5 790,83	442
	Midekicin****	tablet, 400 mg	tablet	64,50	48 781
	Midekicin****	granules for preparation of suspension for ingestion 175 mg/5 ml, 20 g	vial	1 150,82	1 125
	Mirtazapine	tablet, 30 mg	tablet	236,99	19 210
Nest alopecia	Mometazone	Cream 0,1%	tube	2 128,96	8 858
Nest alopecia, dermatitis, Psoriasis	Mometazone	Ointment 0,1%	tube	2 658,14	8 688
Bronchial asthma	Montelukast sodium	Granules, 4 mg	granule/packet	127,50	85 082
Diabetes	Insulin pump kit No. 10 (1.8 ml tank + Infusion kit with 6 mm cannula length) ****.	For every 12 sets, one pump is provided free of charge to all newly identified patients and patients with pumps that have failed	kit	48 471,95	5 656
Diabetes	Insulin pump kit No. 10 (3 ml tank + 9 mm cannula length) ****.	For every 12 sets, one pump is provided free of charge to all newly identified patients and patients with pumps that have failed	kit	48 471,95	792
	Naltrexone ****	extended suspension powder for intramuscular administration, 380 mg	vial	132 760,00	117
	Nandrolone ****	Injection oil solution 50 mg/ml, 1 ml	ampoule	1 160,13	1 852
	Sodium chloride ****	Injection solution 0,9%, 10 ml	ampoule/vial	35,53	475 470

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Malc	Neostagmin****	Injection solution в ампулах 0,05% 1 ml	ampoule	37,18	193 182
	Nimodipine	solution for infusions complete with connective tube for infusion 10 mg /50 ml	vial	3 041,39	30 079
Interstitial lung disease	Nintetanib****	soft capsules, 150 mg	capsule	12 266,81	33 525
Interstitial lung disease	Nintetanib****	soft capsules, 100 mg	capsule	7 418,96	1 440
Ischemic heart disease	Nitroglycerin	aerosol,10 g	vial	1 248,11	37 748
Autoimmune diseases and immunodeficiency conditions		Subcutaneous Injection Solution 165 mg/ml 20 ml	vial	105 458,18	7 937
Autoimmune diseases and immunodeficiency conditions		Subcutaneous Injection Solution 165 mg/ml 10 ml	vial	39 966,47	6 561
	Obimurab****	concentrate for the preparation of infusion solution 1000 mg/40 ml	vial	1 584 230,23	12
	General phospholipids + Double -saturated phosphatidylcholine (DSPC)+free fatty acids (FFA)+Triglycerides (TG)****	suspension for intrachal administration 25 mg/ml, 4 ml	vial	112 730,21	2 288
Multiple sclerosis	Okrilizumab	concentrate to make a solution for infusions 300mg/10 ml	vial	1 564 102,80	272
	Oxycodone naloxone ****	tablet 40 mg/20 mg	tablet	861,84	200
	Oxycodone naloxone ****	tablet 20 mg/10 mg	tablet	493,80	120
	Oxycodone naloxone ****	tablet 10 mg/5 mg	tablet	256,11	0
	Oxycodone naloxone ****	tablet 5 mg/2,5 mg	tablet	133,62	0
	Oxytocin	Injection solution 5 units/ml 1 ml	ampoule	33,21	2 001 308
Trigeminal Nerve Lesions, Epilepsy	Oxcarbazepin****	tablet 300 mg	tablet	47,75	188 930
Hormonally active pituitary tumors . Acromegaly, Chronic Pancreatitis	Octreotide	Injection solution , 0,1 mg/ml	ampoule	1 136,86	59 303
Hormonally active pituitary tumors . Acromegaly, Chronic Pancreatitis	Octreotide	microspheres/lyophilisate for preparation of injection suspensions 20 mg	vial	205 920,21	4 691
	Oloaterol and thiotropy bromide****	solution for inhalations complete with inhaler, 2.5 meq,2.5 meq/1 inhalation	cartridge	14 959,90	599
	Omeprazole	Freeze-dried powder for injection solution 40 mg	vial	691,45	194 970
Gastroesophageal reflux disease, gastric and 12 -finger ulcer disease, chronic pancreatitis, patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation	Omeprazole ****	capsule 40mg	capsule	66,30	709 105
heart, pulmonary, liver, renal failure, gastroesophageal reflux disease, Gastritis and duodenitis	Ofatumumab****	concentrate to make a solution for infusions 100 mg	vial	105 784,39	0
Acute/chronic keratitis	Ofloxacin	eye drops 0,3%	vial	1 876,63	18 461
Mental illness	Paliperidon****	suspension for intramuscular introduction of prolonged action 100 mg/1,0 ml	Syringe	128 378,80	8 508
Mental illness	Paliperidon****	suspension for intramuscular introduction of prolonged action 150 mg/1,5 ml	Syringe	163 213,82	1 682
Mental illness	Paliperidon****	suspension for intramuscular introduction of prolonged action 350 mg/1,75 ml	Syringe	346 622,75	685
Mental illness	Paliperidon****	suspension for intramuscular introduction of prolonged action 75 mg/0,75 ml	Syringe	97 983,94	187
Mental illness	Paliperidon***	suspension for intramuscular introduction of prolonged action 525 mg/2,625 ml	Syringe	438 917,45	174
	Pacidronic acid****	concentrate to make a solution for infusions 3 mg, 10 ml	vial	15 674,96	35
	Panitumumab	concentrate to make a solution for infusions 20 mg/ml (100 mg/5 ml)	vial	172 503,40	997

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Cystic fibrosis (Cystic fibrosis), Chronic pancreatitis	Pancreatin	capsule in an intestine -soluble casing containing minimized spheres , 150 mg	capsule	86,98	2 190 647
Inflammatory Diseases of the Hearing, Cytomegalovirus Disease, Acute Respiratory Infections of the Lower Respiratory Tract, Infections caused by the herpes virus/ Shingles, Osteoarthritis, Chicken Pox, Pneumonia, Skin Infections and Subcutaneous Fiber, Acute Respiratory Infections of the Upper Respiratory Tract, Chronic Pancreatitis, Scarlatin, Gastroenteritis	Paracetamol	tablet 200 mg	tablet	1,82	1 127 383
Chronic pancreatitis, Scarlet fever, Cytomegalovirus disease, Migraine, Pneumonia, Acute respiratory infections of the lower respiratory tract, Chicken smallpox, Skin and subcutaneous fiber infections, Acute respiratory infections of the upper respiratory tract, infections caused by herpes virus / Shingles, Inflammatory diseases of the hearing organs, gastroenteritis and colitis of infectious origin	Paracetamol ****	rectal suppository 250mr	suppository	64,61	461 832
	Pembrolyzumab****	solution for intravenous infusions , 25 mg/ml	vial	1 503 810,02	1 748
Hepato -cerebral dystrophy, Disruptions of transport amino acids	Penicillamin****	tablet 250 mg	tablet	173,78	103 775
	Pertusumab****	concentrate for the preparation of infusion solution 420 mg/14 ml	vial	1 075 296,41	1 630
Male	Pyridostymine bromide****	tablet 60mr	tablet	66,66	1 458 148
	Poractant Alpha	suspension for endotracheal administration 80 mg/ml, 1,5 ml	vial	146 599,25	9 819
Parkinson's disease	Pramipexol****	Tablet extended action , 0,75 mg	tablet	221,84	410 705
Parkinson's disease	Pramipexol****	Tablet extended action , 1,5 mg	tablet	417,47	381 889
	Prednisolone	Injection solution 30 mg/ml, 1 ml	ampoule	80,53	2 682 628
Dermatitis, Erythema multiform, Progressive Glomerular Diseases, Patients with Common Forms of Malignancies, Tuberculosis and HIV Infection, Chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, liver, renal failure, Uzel polyarteritis and related State Other necrotizing vasculopathy, hematological diseases including aplastic anemia, muscular dystrophy, Dermatopolymyositis, Psoriatic arthropathy, ulcerative colitis, Malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplation syndromes, Hive and erythema, Angioeurotic swelling, Bladder, Coeliac, Reactive Arthritis, Bechehet's Disease, Crohn's Disease, Post -Transplant Diseases, Bronchial Asthma	Prednisolone	tablet, 5 mg	tablet	7,93	1 625 746
	Promethazin	Injection solution 25 mg/ ml, 2 ml	ampoule	167,51	35 365
	Propofol****	эмульсия для внутривенного введения 10 mg/ml, 50 ml	vial	1 014,76	138 675
	Propofol****	эмульсия для внутривенного введения 10 mg/ml, 20 ml	vial/ ampoule	567,85	131 020
	Propranolol****	solution for ingestion , 3,75 mg/ml	vial	74 973,42	100
	Anti-diphtheria serum ****	a drug derived from the blood of horses that have been hyperimmunized with diphtheria anatoxin. Serum is a clear or slightly opalescing liquid	ampoule	831,14	690
	Other allergens ****	solution for intracutaneous injection by 3 ml	vial	17 969,08	5 711
	Pagaspargaza****	Injection solution 3750 IU, 5 ml	vial	442 263,57	253
Multiple sclerosis	Peginterferon beta -1a****	Injection solution 125 mcg/0,5 ml	injection pen	140 460,22	2 055

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Multiple sclerosis	Peginterferon beta -1a****	Injection solution 63 mcg/0,5 ml and 94 mcg/0,5 ml	injection pen	89 944,12	248
	Ramucirumab****	concentrate for infusions 10 mg/ml 10ml	vial	357 617,53	1 077
	Ramucirumab****	concentrate for infusions 10 mg/ml 50ml	vial	2 550 221,80	225
	Regorafenib****	tablet, 40 mg	tablet	12 940,80	40 152
Diabetes	Reservoir to pump insulin ***, ****	Volume 1,8 ml	psc	901,82	134 062
Diabetes	Reservoir to pump insulin ***, ****	Volume 3 ml	psc	901,82	59 244
	Rituximab****	subcutaneous injection solution 1400 mg/11,7 ml	vial	576 184,79	282
	Rifampicin***	freeze-dried powder for injection solution, 0.15 g	ampoule	250,39	68 060
Bronchial asthma, Acute respiratory infections of the lower respiratory tract	Salbutamol	100 mcg/dosage aerosol, 200 doses	vial/ баллон	671,59	196 487
Bronchial asthma, Acute respiratory infections of the lower respiratory tract	Salbutamol	solution for nebulizer 5mg/ml volume 20 ml	vial	392,85	88 459
Chronic obstructive pulmonary disease, bronchial asthma	Salmeterolo Fluticazone Propionate	aerosol 25/250 mcg, 120 doses	vial/ баллон	4 994,94	103 554
Chronic obstructive pulmonary disease, bronchial asthma	Salmeterolo Fluticazone Propionate	inhalation powder 50 mcg/250 mcg, 60 doses	Inhaler	8 027,03	80 572
Bronchial Asthma, Chronic Obstructive Pulmonary Disease	Salmeterolo Fluticazone Propionate	inhalation powder 50 mcg/500 mcg, 60 doses	Inhaler	9 134,17	80 046
Bronchial Asthma, Chronic Obstructive Pulmonary Disease	Salmeterolo Fluticazone Propionate	aerosol 25/125 mcg, 120 doses	vial/ баллон	4 227,61	45 701
Chronic obstructive pulmonary disease, bronchial asthma	Salmeterolo Fluticazone Propionate	inhalation powder 50 mcg/100 mcg, 60 doses	Inhaler	6 284,94	28 464
Chronic obstructive pulmonary disease, bronchial asthma	Salmeterolo Fluticazone Propionate	aerosol 25/50 mcg, 120 doses	vial/ баллон	3 226,63	17 333
Chronic kidney disease with renal anemia	Sevelamer****	2.4g oral suspension powder	packet	1 164,37	0
	Sevofluran	liquid/solution for inhalation 250 ml	vial/ bottle	43 781,88	12 849
Hypofunction and other pituitary disorders, pituitary nanism, Shereshevsky -Turner syndrome, Turner Syndrome unspecified	Somatropin	Freeze-dried powder for injection solution complete with solvent , 4 mg, №1	vial	37 073,31	2 742
Hypofunction and other pituitary disorders, pituitary nanism, Shereshevsky -Turner syndrome, Turner Syndrome unspecified	Somatropin	Injection solution , 20 mg, 2.5 ml №1	cartridge	10 509,70	0
Hypofunction and other pituitary disorders, pituitary nanism, Shereshevsky -Turner syndrome, Turner Syndrome unspecified	Somatropin	Injection solution , 12 mg, 1.5 ml №1	cartridge	10 575,73	0
Hypofunction and other pituitary disorders, pituitary nanism, Shereshevsky -Turner syndrome, Turner Syndrome unspecified	Somatropin****	Freeze-dried powder for injection solution complete with solvent 8 mg	mg (cartridge/ Syringe/vial)	5 196,21	139 169
Pituitary nanism, Shereshevsky -Turner syndrome, hypofunction and other pituitary disorders, pituitary nanism, Shereshevsky -Turner syndrome, Turner syndrome unspecified	Somatropin****	6 mg liophilisate for injection solution and injectable	Mr (cartridge/ Syringe/ vial)	5 819,76	51 902
Tuberculosis	Streptomycin****	powder for cooking solution for injection , 1 g	vial	507,66	7 228
	Sugammadex****	solution for intravenous injection 100 mg/ml, 2 ml	vial	38 947,23	1 038
	Succinil gelatin	solution for infusions 4%, 500,0 ml	vial	1 660,45	90 606
	Sulpirid	tablet, 100 mg	tablet	55,88	39 570
Chronic genitourinary infections, Acute/chronic tubulointerstitic jade, urinary tract infection / Cystitis Urethritis and Uretral Syndrome, Toxoplasmosis, Condition after organ and tissue transplantation	Sulfametoxazole and Trimethoprim	tablets, 480 mg	tablet	53,39	468 922

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Acute/chronic tubulointerstitial jade, Chronic genitourinary infections, Toxoplasmosis, Condition after organ and tissue transplantation, urinary tract infection / Cystitis Urethritis and uretral syndrome	Sulfametoxazole and Trimethoprim	tablets, 960 mg	tablet	108,13	145 100
Chronic genitourinary infections, Toxoplasmosis, condition after organ and tissue transplantation, urinary tract infection / Cystitis Urethritis and uretral syndrome, Acute/chronic tubulointerstitial jade	Sulfametoxazole and Trimethoprim	tablets, 120 mg	tablet	28,24	47 627
Psoriatic Arthropathy, Ankylosing Spondylitis, Reactive Arthritis	Sulfasalazine	tablet, 500 mg	tablet	40,82	1 206 784
Cancer	Sunitinib****	Capsules, 12,5 mg	capsule	17 119,67	960
	Surfactant (SF -RI 1) phospholipid fraction of the lung tissue of the bull	lyophilisate for preparation of suspension for endotracheal injection complete with solvent freezeopilisate , 2.4 ml solvent in a syringe 45 mg/ml 108 mg	vial	113 254,56	935
	Teriparatide ****	Solution for subcutaneous administration 250 micrograms/ml, 2.4 ml cartridge in pen injector	pen injector	140 799,38	0
Multiple sclerosis	Teriflunomide ****	tablet 14 mg	tablet	8 109,48	12 793
	Terlipressin ****	injection solution 0,1 mg/ml, 2 ml	ampoule	4 527,62	10 820
Diabetes	Test strips for ketone bodies ****	tube №50	psc	378,59	208 089
	Thiamfenicol****	500 mg liophilisate for injection and inhalation solution	vial	983,87	14 254
	Sodium thiopental ****	freeze-dried powder for the preparation of a solution for injection 1000 mg	vial	877,57	57 520
Chronic obstructive pulmonary disease	Tiotropium bromide ****	Solution for inhalation complete with inhaler, 2.5 micrograms/inhalation	Cartridge	12 599,63	157 425
Chronic obstructive pulmonary disease	Tiotropium bromide ****	capsules with inhaled powder complete with 18 micrograms inhaler	capsule	433,21	94 776
Cystic fibrosis (Cystic fibrosis)	Tobramicin ****	28 mg capsules powder (for every 56 capsules attached 1 Inhaler)	capsule	4 275,17	61 858
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal insufficiency , Chronic heart failure	Thorazemide	prolonged validity tablet 10 mg	tablet	137,36	1 333 635
Rheumatoid arthritis	Tocilizumab****	162 mg/0.9 ml subcutaneous injection solution (for every 8 injections 4 free)	vial	89 744,10	8 808
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal Failure	Tramadol	tablet 100mg	tablet	57,21	527 705
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal Failure	Tramadol	capsule 50mg	capsule	23,77	412 135
Cancer	Trastuzumab ****	Injection solution, 120 mg/ml, 5ml	vial	452 631,58	11 695
	Trastuzumab emtanzin****	freeze-dried powder for the preparation of concentrate for infusion solution 100 mg	vial	759 373,60	897
	Trastuzumab emtanzin****	freeze-dried powder for the preparation of concentrate for infusion solution 160 mg	vial	1 216 062,90	686
	Treosulfan****	preparation powder for infusion solution 1000 mg	vial	56 994,10	430
mental illness	Trihexyphenidil	tablet 2 mg	tablet	5,44	7 948 357
mental illness	Trifluoperazine	tablet, 5 mg	tablet	9,39	3 525 435
	Trifluoperazine ****	Injection solution 0,2%, 1 ml	ampoule	40,83	91 050

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
	Tuberculin	solution containing 2 tuberculin units (TE) in 0.1 ml, which looks like colorless transparent liquid or slightly opalescing, containing sediment and foreign impurities	l	3 136 423,73	293
	Urokinase****	lyophilisate to prepare a solution for infusion of 10,000 IU	vial	8 322,85	657
	Urokinase****	lyophilisate to prepare a solution for infusion of 100 000 IU	vial	31 316,52	385
Chronic obstructive pulmonary disease		aerosol for inhalation dosed 200 doz (10ml)	vial	2 908,67	228 635
Chronic obstructive pulmonary disease		solution for inhalation 500 micrograms/250 mcg/ml, 20 ml	vial	1 358,81	69 536
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal Failure	Fentanyl (Y)	the therapeutic transdermal system 50mg/h	psc	3 662,00	30 532
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal failure	Fentanyl (Y)	the therapeutic transdermal system 75 mg/h	psc	4 472,18	14 444
Patients with common forms of malignancies, tuberculosis and HIV infection, chronic progressive diseases in the stage of decompensation of cardiac, pulmonary, hepatic, renal failure	Fentanyl (Y)	the therapeutic transdermal system 25 mg/h	psc	2 525,85	8 281
Mycoses, Urinary Infections	Fluconazole****	tablet 100 mg	tablet	77,88	11 166
Bronchial asthma	Fluticazone	aerosol dosed for inhalation 250 micrograms/dosage, 120 doses	vial/catridge	5 673,44	17 483
Bronchial asthma	Fluticazone	aerosol dosed for inhalation 125 micrograms/dosage, 60 doses	vial/catridge	2 340,73	15 766
Bronchial asthma	Fluticazone	spray dosed for inhalation 50 micrograms/dosage, 120 doses	vial/catridge	1 625,54	8 701
	Phospholipid fraction isolated from the lung tissue of the bull SF-RI 1 (surfactant)****	freeze-dried slurr powder for suspension endotracheal administration 45 mg/ml complete with solvent 1.2 ml	Syringe/ vial	103 406,34	406
	Chloramphenicol****	injectable solution powder, 1000 mg	vial	349,20	16 514
Mental illness	Chlorpromazine	pill/tablet, 50 mg	pill/tablet	125,21	1 375 600
Mental illness	Chlorpromazine	pill/tablet, 100 mg	pill/tablet	167,15	1 370 350
	Chlorpromazine	injection solution 2,5%, 2 ml	ampoule	64,78	167 270
	Ceritinib****	Capsules, 150 mg	capsule	16 629,14	11 750
Dermatitis, Vasomotor and allergic rhinitis, Hives and erythema, Angioedematous swelling	Cetirizine****	oral solution 120 ml	bottle	1 456,36	14 786
Chronic genitourinary infections, Acute/chronic tubulinterstitial jade	Cefixim****	granules/powder for cooking suspension for ingestion 100 mg/5ml	vial	1 350,11	31 828
Sinusitis / tonsil and adenoid diseases, skin and subcutaneous fiber infections, Lyme disease, cholecystitis/ Holangitis , crack and fistula area of the anus and rectum, pneumonia, chronic genitourinary infections, acute/chronic tubulinterstitial jade	Cefuroxime****	pellets for the preparation of suspension for ingestion 125 mg/5ml	vial	1 614,83	22 973
Bronchial asthma	Ciclesonide****	aerosol for inhalation 160 micrograms/dosage 60 doses	vial	7 043,59	19 239
Bronchial asthma	Ciclesonid	aerosol for inhalation 80 micrograms/dosage 60 doses	vial	6 854,27	7 057
Progressive glomerular diseases, condition after organ and tissue transplantation	Cyclosporine	100 mg/ml solution	vial	34 828,14	272

List of pharmaceuticals and medical devices on the UD List for 2021, not declared by domestic manufacturers

Name of disease (condition)	INN	Dosage form	Units of measure	MH RK ceiling price for 2021	Procurement volume for 2021 on preliminary applications
Systemic sclerosis (systemic scleroderma), node polyarteritis and related conditions; Other necrotizing vasculopathy, Psoriasis, Dermatopolisitis , Crohn's disease, Psoriatic arthropathy, juvenile arthritis, malignant lymph tumors , Progressive glomerular diseases	Cyclophosphamide	injectable solution powder, 500 mg	vial	3 260,16	12 179
Progressive glomerular diseases, Systemic sclerosis (systemic scleroderma), node polyarteritis and related conditions; Other necrotizing vasculopathy	Cyclophosphamide	injectable solution powder, 1000 mg	vial	5 501,88	5 534
Systemic sclerosis (systemic scleroderma), node polyarteritis and related conditions; Other necrotizing vasculopathy, Progressive glomerular diseases, Systemic sclerosis (systemic scleroderma), node polyarteritis and related conditions; Other necrotizing vasculopathy	Cyclophosphamide ****	tablet 50 mg	tablet	95,17	570
Cancer	Ciproteron	oil solution for intramuscular injections 300 mg/3 ml, 3 ml	ampoule	3 267,82	9 186
Malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasion syndromes	Citarabin****	freeze-dried powder for the preparation of the solution for injection 100 mg / injection solution and infusions 100 mg	vial	879,68	17 711
Malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasion syndromes	Citarabin****	freeze-dried powder for the preparation of a solution for injection 1000 mg / injection solution and infusions 1000 mg	vial	3 916,19	4 280
	Human normal immunoglobulin G	10% infusion solution, 50 ml	vial	120 482,85	2 774
	Everolimus***	tablet, 0,25 mg	tablet	765,69	2 880
	Everolimus***	tablet, 0,75 mg	tablet	1 407,21	0
Mukopolisacharidosis	Elosulfaza alpha	concentrate for preparing a solution for infusion 1 mg/ml, 5 ml	vial	413 208,53	2 332
Hematological diseases, including aplastic anemia, malignant tumors of lymphoid, blood -forming and related tissues, including myelodisplasion syndromes	Eltrombopag ****	tablet 50 mg	tablet	30 533,10	53 974
Hereditary deficits of blood clotting factors	Emizizumab	60 mg/0.4 ml injection solution	vial	1 908 419,90	435
Hereditary deficits of blood clotting factors	Emizizumab	30 mg/1 ml injection solution	vial	954 209,95	360
Hereditary deficits of blood clotting factors	Emizizumab	105 mg/0.7 ml injection solution	vial	3 339 734,80	69
Hereditary deficits of blood clotting factors	Emizizumab	150 mg/1 ml injection solution	vial	4 771 049,70	54
	Epinephrine	0.18% 1 ml injection solution	ampoule	62,11	343 562
Celiac disease, Rahit	Ergocalziferol ****	oil solution for ingestion 0.125% 10ml	vial	335,45	121 508
Scarlet fever, Acne disease	erythromycin****	tablet 250 mg	tablet	22,96	143 754
Tuberculosis	Ethambutol	injection solution, 10% 20ml	vial	5 513,05	44 928



**COMPREHENSIVE PLAN FOR THE
DEVELOPMENT OF THE
PHARMACEUTICAL AND
MEDICAL INDUSTRIES
FOR 2020-2025 JSC**

THE STRUCTURE OF THE COMPLEX PLAN

8

SECTIONS

62

EVENTS

**2020 -
2025 гг.**

IMPLEMENTATION PERIOD

1
**REGULATION OF
THE DOMESTIC
MARKET**

2
**REGULATION
WITHIN THE EAEU**

3
STATE SUPPORT

4
R&D

5
**ATTRACTING
INVESTMENT**

6
STAFF

7
MARKING

8
**INCREASED
CAPACITY OF DM**

A COMPREHENSIVE PLAN FOR THE DEVELOPMENT OF THE PHARMACEUTICAL INDUSTRY

SECTION

LEGISLATIVE AND REGULATORY REGULATION

TASKS

SIMPLIFICATION ACCESS TO MARKET FOR RISK AND INVESTORS

INCREASE IN THE SHARE OF DOMESTIC PHARMACEUTICAL PRODUCTION IN PURCHASES

REDUCING THE TIMING OF THE PURCHASE AND DELIVERY OF PRODUCTS

17 EVENTS

- ✓ Indefinite validity of reg. certificates for pharmaceuticals and medical devices
- ✓ Develop a procurement order within the framework of contract production
- ✓ KPI approval for local content at regional levels
- ✓ Determining the terms of delisting, under long-term contracts
- ✓ Transfer of price registration services and re-registration of the registered price for pharmaceuticals into the format of public service
- ✓ Revising quality assessment approaches in the post-registration period

COMPREHENSIVE PLAN FOR THE PHARMACEUTICAL INDUSTRY

II SECTION

TREATMENT OF MEDICINES AND MEDICAL PRODUCTS WITHIN THE EAEU

TASKS

HARMONIZATION OF
REQUIREMENTS WITHIN
THE EAEU

INTRODUCTION OF EAEU
STANDARDS TO
PROMOTE EXPORTS

REDUCING THE COST OF
DOMESTIC PRODUCTS

6 EVENTS

- ✓ Preservation of the appeal of the pharmaceuticals on national procedures in parallel with the procedures of the EAEU
- ✓ Development of Kazakhstan's GLP-compliant laboratories
- ✓ Development of clinical bases that meet the requirements of GSP
- ✓ Reducing import customs duties for substances, raw materials and components for the production of pharmaceuticals and Medical devices

III SECTION

MEASURES OF STATE SUPPORT

TASKS

**IMPROVING THE PRICE
COMPETITIVENESS OF
DOMESTIC PRODUCTS**

**INCENTIVES TO EXPAND
AND INCREASE
PRODUCTION**

6 EVENTS

- ✓ Reimbursement of costs for clinical and preclinical trials
- ✓ Reimbursement of 50% product labelling costs
- ✓ Expansion of SEZ "Ontustik" and SEZ "PIT".
- ✓ Subsidizing the cost of importing raw materials
- ✓ State support for drug investment projects (vaccines, test systems, etc.)

IV SECTION

RESEARCH AND DEVELOPMENT AND DEVELOPMENT WORKS

TASKS

DETERMINING THE PROMISING DIRECTIONS OF THE PHARMACEUTICAL AND MEDICAL INDUSTRY

THE DEVELOPMENT OF BIOMEDICINE SCIENCE

9 EVENTS

- ✓ Analysis to further localize production in Kazakhstan
- ✓ Determining the demand for the development of domestic and localization of foreign technologies
- ✓ Development of biofactories and the creation of bioproduction to control disease and plant pests
- ✓ Production of drugs using medicinal plants
- ✓ Improving the competitiveness of domestic producers of dietary supplements and other plant-based drugs

COMPREHENSIVE PLAN FOR THE PHARMACEUTICAL INDUSTRY

V SECTION ATTRACTING INVESTMENT

TASKS

IMPROVING THE
INVESTMENT CLIMATE

CREATING NEW
PRODUCTIONS WITH
WORLD PLAYERS

4 EVENTS

- ✓ Preparing investment proposals to target global pharmaceutical manufacturers
- ✓ Building a positive image of Kazakhstani manufacturers
- ✓ Attracting 4 TNCs from Big Pharma - Top 50



COMPREHENSIVE PLAN FOR THE PHARMACEUTICAL INDUSTRY

VI SECTION **INDUSTRY STAFFING**

TASKS

STRENGTHENING HUMAN RESOURCES

4 EVENTS

- ✓ Forming an educational order tailored to the needs of manufacturers of pharmaceuticals and medical devices
- ✓ Actualization of professional standards, harmonization with the national qualification framework
- ✓ Training in universities of specialists to work with biological agents
- ✓ Organization of scientific internships for specialists in biological safety, medicine and pharmaceuticals

COMPREHENSIVE PLAN FOR THE PHARMACEUTICAL INDUSTRY

VII SECTION

DRUG LABELING AND TRACEABILITY

TASKS

IMPROVING PRODUCT
QUALITY

REDUCING THE SHADOW
ECONOMY

6 EVENTS

- ✓ Pilot project of labeling and traceability of pharmaceuticals
- ✓ Introducing alternative ways of labelling pharmaceuticals
- ✓ Determining the list of pharmaceuticals and stages of introduction of mandatory pharmaceuticals labelling
- ✓ Changes and additions to the LSI in terms of the introduction of mandatory labeling pharmaceuticals
- ✓ Working out the issue of expanding the list of goods to be labelled (BAS and other medical products)

THE EFFECT OF IMPLEMENTING A COMPREHENSIVE PLAN



No less
30
new projects



180
million USD



2 000
new jobs



297
New kinds
of pharmaceuticals



2 348
New kinds of
medical products

THE EFFECT OF IMPLEMENTING A COMPREHENSIVE PLAN



Increase in output

2,5
times

92 to 230
billion tenge



Growth Export

3
times

58 to 174
million USD



Growth in the
production of masks

2
times

1 to 2
million pieces
per day



Growth production of
protective suits

2
times

504 to 1050
million pieces per
month



The share of DM
products in the
RK market
(In real terms)

39%
now

50%
Will be




KAZAKH INVEST
NATIONAL COMPANY

PREFERENCES FOR INVESTMENT PROJECTS



KAZAKH INVEST - NATIONAL OPERATOR FOR INVESTMENTS ATTRACTION



Interaction with potential investors abroad through overseas representatives and in the regions through regional representatives

INVESTMENT PREFERENCES

Preferences	Investment project	Investment priority project		Special investment project
		SETUP OF NEW PRODUCTION FACILITIES (FABRICS, PLANT,SHOP)	EXPANDING OR UPDATING EXISTING PRODUCTIONS (RENOVATION, RECONSTRUCTION, MODERNIZATION)	
CUSTOMS DUTY EXEMPTION	+ / 5 years	+ / 5 years	+ / 5 years	+ / 15 years
STATE IN-KIND GRANT	+ Max value size - 30% of investments amount	Max value size - 30% of investments amount	Max value size - 30% of investments amount	————
TAX PREFERENCES				
STATE IN-KIND GRANT	+ / 5 years	————	————	+ / Force period of special investment contract
Corporate income tax	————	+ / 10 years	+ / 3 years	————
Land tax	————	+ / 10 years	————	————
Property tax	————	+ / 8 years	————	————
INVESTMENT SUBSIDY		Minimum investments amount is 5 mln. monthly assessment indices (approx.. \$US 32 000 000) Priority business activities against the section 3 Decree No.13 of 14.01.2016	————	

PREFERENCES FOR INVESTMENT PROJECTS (CONTINUED)

INVESTMENT PREFERENCES	INVESTMENT PROJECT	INVESTMENT PRIORITY PROJECT	SPECIAL INVESTMENT PROJECT
<p>TERMS OF DELIVERY</p>	<p>1) Recipient - applicant: Legal entity, duly registered in the Republic of Kazakhstan</p> <p>1) Priority business activities against the sections 1 and 2 Decree No.13 of 14.01.2016</p>	<p>1) Recipient - applicant: Legal entity, duly registered in the Republic of Kazakhstan</p> <p>2) Priority business activities against the section 2 Decree No.13 of 14.01.2016</p> <p>3) Minimal investments amount on the date of submitting an application: <ul style="list-style-type: none"> •2,000,000 monthly assessment indices, KZT 5,506 bln. or. nearly \$ US 13,000 mln. (exchange rate \$1USD – KZT 430) for building new production facilities; or 5,000,000 monthly calculation indices, KZT 13 890 bln. or. \$US KZT 32 mln.. for upgrading and expansion of production facilities; •A legal entity – applicant cannot be:: <ul style="list-style-type: none"> • Autonomous educational organization; • Member of Special Economic Zone; <p>1.Government shareholding: <ul style="list-style-type: none"> - Maximum 50% for investment priority project in the area of machine manufacturing, including foundry production and projects on coal beds methane production; - Maximum 26% for all other projects. <p>2.Shareholding period as a founder or shareholder : <ul style="list-style-type: none"> •Maximum 20 years for investment priority projects in machine manufacturing, including foundry production, from time of registration of investment contracts; •Maximum 5 years from the time of registration of investment contract for all other projects, except for projects on coal beds methane production. <p>In the event of failure of shareholding period condition above, the investment preferences shall be suspended up to complete resigning of state or quasi-state entities from the founders and/or participatory shareholders of a legal entity of the RK, but not longer than one year.</p> <p>1) No public partnership agreement, inter alia concession agreement, was made for carrying out investment activity, including the concession project;</p> </p></p></p>	<p>Recipient-applicant: 1) Duly registered participant of Special Economic Zone under laws of the Republic of Kazakhstan on special economic zones;</p> <p>2) Duly registered holder of free customs zone under the customs laws of the Republic of Kazakhstan;</p> <p>3) Manufacturers of vehicles and/or constituent elements of them, farm machinery and/or their constituent elements subject to agreement on industrial assembly.</p>

LEGAL DEFINITIONS

Investments shall mean any types of property, (except those for private consumption), inter alia financial leasing items under a leasing contract signing and rights to them, invested into the registered capital of a legal entity or for the fixed assets increase, designated for the business activity, inter alia public private partnership project, including a concession one. (point 1 article 274 Entrepreneurial Code of the Republic of Kazakhstan (EC RK))

Investors shall mean individuals and legal entities investing into the Republic of Kazakhstan. (point 1 article 274 EC RK)

Investment activities shall mean contributing into the registered capital of commercial organizations or creating or increasing fixed assets by individuals and legal entities in frames of the business activity and development of public private partnership projects (PPP project), inter alia a concession one (point 3 article 274 EC RK).

A big investor shall mean an individual or a legal entity making investments amount approx. at least \$ nearly US 13,000 (two million – fold of Kazakhstani monthly assessment index (MAI, 2778 for 2020) in the Republic of Kazakhstan.

RESTRICTIONS

- Foreign legal entities and individuals, and stateless persons are not allowed to have and hold, use and dispose directly or indirectly more than 20 per cent of shareholding, participatory interests, contributions of a legal entity – owner of a mass media entity in the Republic of Kazakhstan or operating in mass media area. (sub-point 3) point 6 article 23 National Security Law of the Republic of Kazakhstan). This provision does not apply to internet-resources for electronic commerce; (sub-clause 3) of clause 6 of Article 23 of the Law of RK "On National Security of the Republic of Kazakhstan")
- Foreigners, stateless persons and foreign legal entities are not allowed to manage or use trunk communication lines without setting up a legal entity in the territory of the Republic of Kazakhstan;
- Setting up and managing a communication system in the territory of the Republic of Kazakhstan with a control centre beyond its borders shall be forbidden. (sub-clause 4), 5) clause 6, article, 23 National Security Law of the Republic of Kazakhstan)
- (sub-clause 3) clause 6 of Article 23 of the National Security Act of the Republic of Kazakhstan)
- Individuals and legal entities are not allowed to have and hold more than 10 per cent of voting shares, participatory interests and contribution shares in organisation, which owns and/or manages or operates communication lines as a national and international carrier without consent of the authorised state body in the sphere of communication and information and national security agency;
- Foreigners, stateless persons and foreign legal entities are allowed to have and hold directly and/or indirectly more than 49 per cent of voting shares, participatory interests and contribution shares of a legal entity which carries out its activity in telecommunication sphere as a national and/or international carrier and which owns land (cable, including fiber-optic, radio-relay) communication lines subject to approval of the authorized state agency.
- (sub-point 6), 7) point 6, article, 23 National Security Law of the Republic of Kazakhstan)

GUARANTEE OF INVESTOR RIGHTS PROTECTION

The Republic of Kazakhstan guarantees stability of terms of agreements between investors and state bodies of the Republic of Kazakhstan, unless the changes are made upon mutual consent of both parties. This shall not apply to:

1) changes in laws of the Republic of Kazakhstan and (or) entry into force and (or) changes of international agreements of the Republic of Kazakhstan triggering change of procedures and conditions of import, manufacture and sale of excised goods;

2) changes and additions into the laws of the Republic of Kazakhstan that are made to ensure national security, social order, health care and public morals. (clause 3 article 276 EC RK)

An investor may :

- 1) at its own discretion use incomes gained through the investing activity subject to payment of the taxes and mandatory payments into the budget pursuant to the laws of the Republic of Kazakhstan;

- 2) open bank accounts in any banks in the territory of the Republic of Kazakhstan in national and foreign currency pursuant to the laws of the banking and currency laws of the Republic of Kazakhstan.

(Article 277 EC RK)

GUARANTEE OF INVESTOR RIGHTS PROTECTON

Requisition

The investors' property requisition shall be carried subject to payment of a market value of the expropriated property to the investor. The market value should be determined as per the procedures, established by the laws.

The compensation value of the property can be claimed in manner, established by the laws. Upon termination of circumstances, that triggered requisition was made, an investor may demand to return the remained property, but has to pay back the compensation amount, taking into account losses due to property cost reduction.

Nationalization

Nationalisation of investors' property shall be carried subject to the reimbursement by the Republic of Kazakhstan to the investor of full amount of all damages, caused through the adoption of nationalization legal acts of the Republic of Kazakhstan (*The losses shall mean expenditures that have to be made by a person or entity, whose right is violated and loss or damage of its property (actual damage), also non-gained profit, which could be gained under usual circumstances, if its rights have not been violated (expected profit loss).

(clause 4 article 9 Civil Code of the Republic of Kazakhstan (General part).

Statutory and regulatory enactments to conclude a special investment contract

On the approval of a model special investment contract. The Order of the Minister for Investment and Development of the Republic of Kazakhstan dated February 7, 2017 No. 75. Registered with the Ministry of Justice of the Republic of Kazakhstan on February 15, 2017 No. 14806.

On the approval of the Rules and conditions of the conclusion and termination of a special investment contract. The order of the Acting Minister for Investment and Development of the Republic of Kazakhstan dated February 8, 2017 No. 85. Registered with the Ministry of Justice of the Republic of Kazakhstan on February 14, 2017 No. 14801.

On the approval of the application form for the provision of investment preferences within the framework of the implementation of a special investment project and the rules of its reception and registration. The Order of the Minister for Investment and Development of the Republic of Kazakhstan dated February 6, 2017 No. 74. Registered with the Ministry of Justice of the Republic of Kazakhstan on February 14, 2017 No. 14800.

INVESTMENT PREFERENCES

EXEMPTION FROM CUSTOMS DUTIES

- Technological equipment - goods intended for use in the process of an investment project. Components are components that combine to comprise the constructive integrity of technological equipment and are included in the relevant list of goods drawn up by the Customs Union Commission. Raw materials and/or materials are any mineral, component, part or other product used to produce finished products through the process of an investment project, provided there is no production of this raw material and/or materials in the territory of the Republic of Kazakhstan.

- Exemption from customs duties on the import of technological equipment and components to it is granted for the duration of the investment contract, but not more than five years from the date of registration of the investment contract. Notification of the decision is sent to the investment authority within five working days to the customs authority. (Article 287 EC RK)

Recipient:

1) A legal entity of the Republic of Kazakhstan implementing an investment project within the framework of: investment contract

- investment priority contract

when importing technological equipment, components and spare parts to it, raw materials and/or materials in accordance with the legislation of the Customs Union and/or the legislation of the Republic of Kazakhstan. 2) Under a special investment contract

- participants in special economic zones for fifteen years, but no longer than the duration of special economic zones;
- Owners of vacant warehouses for a period of no more than fifteen years from the date of registration of a special investment contract;
- legal entities of the Republic of Kazakhstan, who have entered into an agreement on the industrial assembly of motor vehicles, for a period of no more than fifteen years from the date of registration of a special investment contract.

3) A legal entity is a leasing company for the import of technological equipment supplied as part of the investment project under a financial leasing agreement for the legal entity of the Republic of Kazakhstan implementing the investment project.

INVESTMENT PREFERENCES

STATE IN-KIND GRANT

Content

Land, buildings, facilities, machinery and equipment, computing equipment, measuring and regulating devices and devices, vehicles (except cars), industrial and household equipment

Assessment of state in-kind grant is carried out at their market value in accordance with the law of the Republic of Kazakhstan.

Amount

The maximum amount of the state in-kind grant is no more than 30 (thirty) percent of the investment in fixed assets of the legal entity of the Republic of Kazakhstan. Documents confirming the amount (cost) of the state in-kind grant must be attached to the application

Pre-consent

In accordance with paragraph 14 of the Applications for Preferences approved by the Order of the Minister for Investment and Development of the Republic of Kazakhstan on November 30, 2015 No. 1133, a document confirming the receipt of a state-run grant is required prior consent of the local executive.

INVESTMENT PREFERENCES

INVESTMENT SUBSIDY

AMOUNT OF INVESTMENT

Investment subsidy is a type of budget subsidy provided as an investment preference on a non-refundable and non-repayable basis to a legal entity of the Republic of Kazakhstan that has concluded an investment contract providing for investments of at least five million times the amount of the monthly calculation index.

GOVERNMENT DECISION

In order to promote regional development, an investment subsidy is provided on the basis of the decision of the Government of the Republic of Kazakhstan to the investor implementing the investment priority project.

AMOUNT

- The investment subsidy is provided by recovering up to thirty per cent of the cost of construction and installation work and the purchase of equipment, excluding value-added tax and excise taxes provided by the investment contract working programme.
- The payment of an investment subsidy on the actual costs of construction and installation work and the purchase of equipment is made on the basis of supporting documents, but does not exceed the cost of the costs provided by the pre-project documentation, which has the conclusion of the state examination in the order defined by the legislation of the Republic of Kazakhstan.

PRIORITY ACTIVITIES

- The investment subsidy is provided on priority activities set out by the Government of Kazakhstan to provide an investment subsidy. (Part 3 Of The Regulations of 14.01.2016 No 13)


DOCUMENTS

- 1) Primary accounting documents issued in accordance with the laws of the Republic of Kazakhstan on accounting and financial reporting;
- 2) Invoices issued in accordance with the tax laws of the Republic of Kazakhstan;
- 3) customs declarations issued in accordance with the customs laws of the Republic of Kazakhstan.
5. The schedule and annual payments of the investment subsidy are set under the investment contract by distributing the investment subsidy in equal shares for a period of at least three years, but no longer than the term of the investment contract.
6. The payment of the investment subsidy is made in coordination with the local executive body of the region, the city of republican importance and the capital at the place of implementation of the project after the commissioning of production in full, subject to the implementation of production indicators set by the investment contract.
7. The rules for granting an investment subsidy are approved by the Government of Kazakhstan.

GUARANTEES OF STABILITY WHEN CHANGING THE LAW OF THE REPUBLIC OF KAZAKHSTAN

Legal entities implementing investment priority projects, as well as implementing special investment projects and strategic projects under investment contracts concluded before January 1, 2015, are guaranteed stability when the change: tax legislation of the Republic of Kazakhstan in accordance with the Code of the Republic of Kazakhstan "On taxes and other mandatory payments to the budget" (Tax Code);

- Kazakhstan's employment laws to attract foreign labour.
- The application of the guarantee of stability of the legislation of the Republic of Kazakhstan will be annulled in the event of an early termination of the investment contract in accordance with this Code. (Article 289 EC RK)






DEVELOPMENT OF THE PHARMACEUTICAL INDUSTRY IN KAZAKHSTAN

THE CURRENT STATE OF THE PHARMACEUTICAL INDUSTRY

There are **96** pharmaceutical enterprises:

- **33** On medicines
- **41** Medical DEVICES
- **22** medical equipment



2019

Production

92,4 +18,3%
Billion KZT

Investments

8,1 +5,2%
Billion KZT

Export

58,9 +69%
Million US dollars

8 months of 2020

Production

81,5 +34,1%
Billion KZT

Investments

4,1 +5,2%
Billion KZT

Export*


32,9 +2,9%
Million US dollars

4 Transnational companies are operating in the market of Kazakhstan




64% products are manufactured by enterprises with the participation of transnational corporations

Domestic manufacturers share in pharmaceutical and medical devices procurement Up to 30% or 55 billion KZT.







delivered solid results in a challenging market

ANALYTICAL REVIEW OF THE PHARMACEUTICAL INDUSTRY




DESPITE THE HIGH DYNAMICS OF PHARMACEUTICAL GROWTH, IT HAS A SMALL SHARE IN KAZAKHSTAN'S ECONOMY (SHARE OF GDP: 0,29%)



Data for 9 months. 2019
Sources: CS MNE RK


ENTERPRISES IN THE INDUSTRY SPECIALISE
IN LOW VALUE-ADDED PRODUCTS.




DOMESTIC PRODUCTS STILL OCCUPY A LOW SHARE EVEN IN THE RELATIVELY SMALL DOMESTIC MARKET OF THE COUNTRY

Kazakhstani manufacturers occupy a small part of the country's market

The structure of the pharmaceutical market in monetary terms in 2019




Production and import dynamics, 2010-2019



Comments

- Kazakhstan still imports medicines and medical devices (86.2%) from the world leaders in the pharmaceutical market: Germany (18%), Russia (11%), France (8.7%), etc.
- Up to 90% of pharmaceutical substances are imported from foreign countries: China, India and Europe.
- share of medicinal substances in the production of the drug itself is 20-50%.
- During the COVID-19 outbreak, many pharmaceutical manufacturers are experiencing difficulties purchasing active pharmaceutical substances due to border closures in China and India.
- To ensure national security of the state the share of domestic pharmaceutical products must be at least 30%

IN THE SEGMENT OF MEDICAL PRODUCTS THERE IS A HIGH IMPORT DEPENDENCE



Comments

There is a high dependence on imported medical products, as well as raw materials and equipment for the production of products.


- The main restraining factors for the development of the medical devices

Lower prices for products supplied under the FAFMC, which may lead to a further decrease in production, a reduction in the range of products and jobs in the segment of production

Requirements for medical devices in regulatory legal acts are set out in the context of requirements for medicines, which creates financial losses for manufacturers

Lack of a list of laboratories accredited by the Ministry of health to conduct technical tests, routine and reference measurements of medical

DURING THE COVID-19 OUTBREAK, THE NEED FOR MEDICAL MASKS AND VENTILATORS INCREASED




COMMENTS

- In Kazakhstan, only 8 pharmaceutical companies produce medical masks.
- To prevent coronavirus infection and ensure national security, more than 35 light industry rebuilt production to make prophylactic protective masks. Now the production of medical masks per day is 339.2 thousand units, Preventive protective masks – 716,8 Thd. Pcs.
- Tynys LLPs produce ventilators to meet the domestic needs of Kazakhstan (500 units / month).
- It should be noted that during the COVID-19 outbreak, medical mask manufacturers experienced difficulties in purchasing raw materials (filters, elastic bands, nanosheets) for the production of masks due to the closure of borders in China, as well as the increase in the cost of raw materials (filters 15 times, elastic bands 6 times, nanosheets 2.5 times) and equipment (6 times).

THE VOLUME OF R & D FUNDING IN KAZAKHSTAN IS AT A LOW LEVEL COMPARED TO THE WORLD LEADERS IN THE PHARMACEUTICAL INDUSTRY

In terms of R & d funding, Kazakhstan is significantly behind the world leaders

Funding for research and resources in Pharmaceuticals, 2018, billions of dollars. United States



COMMENT

- In Kazakhstan, there are no large pharmaceutical companies that can finance large-scale research projects to create original drugs from their own funds in the amount of several billion dollars a year.
- The markets of the United States, Europe and Japan (Big Pharma) are dominated by large corporations, allocating 9-20 billion dollars. U.S. year to carry out research.
- The average cost of developing the original drug is 1-5 billion dollars. U.S., and the entire development period can last up to 10 years.
- The volume of R & D funding in the pharmaceutical industry in Kazakhstan exceeds 30 million US dollars per year.

GROWING DISEASES IN KAZAKHSTAN CREATES DEMAND FOR PHARMACEUTICAL PRODUCTS




COMMENTS

When manufacturing pharmaceutical products in Kazakhstan, it is worth paying attention to the emerging trends in the structure of diseases

The most popular drugs and medical devices in public procurement:

- vaccines for humans (pneumococococoten, against diphtheria, hepatitis B, etc.) drugs for cancer
- drugs for the treatment of haemophilia A drugs to treat tuberculosis
- drugs to treat chronic hepatitis C antiviral drugs for treatment HIV infection a remedy for multiple sclerosis
- preparations for the treatment of sugar DiabetesExpress test
- sterile and unsterile gloves surgical kit
- masks medical

DEVELOPING COUNTRIES HAVE ADVANTAGES IN CLINICAL RESEARCH, GENERIC AND PHYTOPRIIPATES, AND CAN CARRY OUT PART OF RESEARCH AND DEVELOPMENT FOR INTERNATIONAL COMPANIES



- Developed countries are represented in all drug segments and stages of the value chain
- However, R & d and clinical trials are being outsourced to developing countries

● The segment is clearly expressed in the country x The segment is absent

- Developing countries are actively involved in the production of generics and phyto-drugs, conducting research for the needs of international companies and clinical research due to low cost, as well as to production of substances (due to low production costs)

▭ Opportunities for Kazakhstan



MINISTRY OF INDUSTRY AND INFRASTRUCTURAL DEVELOPMENT OF RK

Administrator of state incentive measures :

- on productivity improvement;
- on promotion domestic processed
- goods, works and services in the domestic market



MINISTRY OF TRADE AND INTEGRATION

Administrator of state incentive measures

- on promotion domestic processed goods to foreign markets

Operator for provision of state incentive measures **JSC “QazIndustry Kazakhstan Industry and Export Center”**

PARTIAL RECOVERY OF COSTS:

- ✓ To improve labour productivity (industrial efficiency)
- ✓ To promote domestic processed goods on foreign markets (export)
- ✓ To promote domestic processed goods, works and services in the domestic market (quality)

ENTREPRENEUR

ENTREPRENEUR

for the purpose of production development and the enterprise as a whole invests financial resources

- ✓ **Qualified staff**
- ✓ **High-performance Equipment**
- ✓ **A wide range of products**
- ✓ **High-quality products**
- ✓ **Modern management and manufacturing technologies**
(automation, digitalization)
- ✓ **Product promotion (Sales)**

IMPROVING PRODUCTIVITY

IMPROVING PRODUCTIVITY

size: **40%**

amount: **no more than 30 million KZT**

historical period: **24 months**

- advanced training of engineering and technical personnel, production personnel, including top managers (Kazakhstan and abroad);
- Employment of a foreign employee under an employment contract (including product promotion).

COMPREHENSIVE PLAN OF INDUSTRIAL INNOVATIVE PROJECT

Size: **40%**

Amount: **no more than 60 million KZT**

historical period: **24 months**

- development of a comprehensive plan of industrial and innovative project to obtain long-term leasing financing;\
- development and/or examination of the feasibility study for the project included in the Map

OPERATIONAL IMPROVEMENT

Size: **40%**

Amount: **no more than 60 million KZT**

historical period: **24 months**

- tech/energoaudit;
- IT consulting;
- consulting on solving a set of problems associated with the formation, reorganization and operation of the company's management system;
- industrial design of products;
- engineering design and solution,
- search for new constructions, technologies and equipment;
- installation, supervision, commissioning of equipment;
- virtual commissioning of equipment;
- engineering, design developments;
- digital and virtual engineering developments;
- manufacturing of prototypes and/or digital modeling;
- equipment maintenance;
- product acceptance testing;
- augmented reality implementation

IMPROVING EFFICIENCY

MANUFACTURING ORGANIZATIONS

Size: **40%**

amount: **no more than 60 million KZT**

historical period: **24 months**

- development of documentation and/or implementation of advanced management and production technologies (ACS, (software); energy efficient and green technologies);
- Project Management Standards;
- Lean manufacturing elements (Kaizen, TPM, Six Sigma, 5 S, Kanban and others);
- introduction of technology (elements) Industry 4.0.

PRODUCTIVITY IMPROVEMENT

WHO CAN GET A REFUND?

Businesses operating in priority sectors of the economy for at least 1 year*

** Except for enterprises with state participation*

**Appendix 1 to
The Rules**

WHERE CAN I SEE THE CONDITIONS, THE LIST OF DOCUMENTS?

Rules for providing state support to the subjects of industrial and innovative activity aimed at increasing labour productivity and developing territorial clusters

**Order of the Minister of
Investment and
Development of RK
dated 9.12.2015 No.1194**

HOW CAN I APPLY?

Through the Internet -portal www.qazindustry.gov.kz in the section "Business Support".

**application period
all year round**

HOW LONG DO YOU CONSIDER THE APPLICATION?

filing
electronical
application

20 min

Registration
of electronical
application*

10 min

Expertise,
yes/no
solution

10 w. d.

Sending
Agreement

1 w. d.

Refund
Cost

2 w. d.

**Total term
13 working
days**

**The application is registered the day after it enters the system*

*Since the signing of the Cost recovery and cash recovery agreement
For 2 years, the implementation of counter-commitments has been monitored*

PRODUCTIVITY IMPROVEMENT

AMENDMENTS TO THE RULES ON PARTIAL REIMBURSEMENT OF EXPENSES

By Order of the Minister of Industry and Infrastructure Development of the Republic of Kazakhstan No. 348 dated June 12, 2020, the following amendments and additions were made to the current Rules on reimbursement of a part of the costs of increasing productivity:

- **the rule regarding the applicant's affiliation** with state bodies and organizations is excluded (paragraph 3 of the Rules);
- it provides for reimbursement of expenses related to attracting foreign employees under an employment contract or a contract for the provision of paid services for the purpose of promoting products (services) (sub-paragraph 1) of paragraph 12 of the Rules);
- the program provides for reimbursement of costs for applications where the service (work) contracts provide for a range of services (works) for recoverable and non-recoverable expenses. Thus, if compensation only takes into account the amount of recoverable costs specified in the contract (subparagraphs 4), 5), 6) paragraph 29 of the Regulations);
- **expanded the list of documents** on the cost of installation supervision, installation, commissioning and maintenance of equipment and production of prototype (subparagraphs 4), 5) of paragraph 30 of the Regulations), and also on attraction of the foreign worker (paragraph 31 of the Rules);
- it provides the right to request additional documents and make a visit to the applicant's production facility if necessary (paragraph 32 of the Rules);
- it provides the right to make a trip to the applicant's production facility, the costs of which were reimbursed within the framework of the provided support measure (paragraph 42 of the Rules);
- the procedure for providing the state service "Reimbursement of costs for the development and/or examination of a comprehensive plan for an industrial and innovative project" through the State Corporation "Government for citizens" is provided (Chapter 4 of the Rules)
- **the CCEA codes are excluded From the list of priority sectors of the economy** (09 - technical services in the field of mining, 09.1-Technical services in the field of oil and natural gas production, 09.10-Technical support for oil and natural gas production, 09.9-Technical support for other areas of mining and underground development, 52-Warehousing and auxiliary transport activities, 61-Communications, 62-Computer programming, consulting and other related services);
- **counter obligations of the applicant** are provided for: increase of the volume of income of the enterprise from sale of products and rendering of services by at least 10%, increase of tax deductions by at least 10% (according to CIT), including change of the period of achievement of target indicators of state support measures - within 2 years from the moment of signing of the act (acts) of rendered services (performed works) on reimbursable expenses), and also return of the received measures of state support by the applicant in full in case of non-achievement of target indicators (Annex).
- amendments were made to the Application and Report forms (Annex 2 and 3 to the Rules, respectively)

PROMOTION OF DOMESTIC PROCESSED GOODS TO FOREIGN MARKETS

size: **40, 50, 60%** (кр, ср, мал бизнес)
amount: **no more than 13,000 MCI historical**
period: **32 months**

DELIVERY OF GOODS

DELIVERY OF GOODS

Size: **50%**

Amount: **no more 1/50 from budget**
historical period: **12 months**

- Railway;
- Air;
- Automotive;
- Sea transport;
- Transportation organization

PARTICIPATION IN FOREIGN EXHIBITIONS, FAIRS, FESTIVALS

- registration fee;
- rental of exhibition space;
- production (lease), installation/dismantling of exhibition stands, additional equipment;
- development, design and decoration of exhibition areas;
- development, design, translation and production of advertising and distribution materials;
- economy class flight for 2 employees;
- accommodation for 2 employees

PRODUCT ADVERTISING

- in mass media (print, television, radio, Internet resources);
- in public places (banners, stretch marks, light boxes, broadcasting of audio-video clips, advertisement on outdoor surfaces and saloons of vehicles);
- production of audio-video clips and advertising materials, lease of advertising structures and surfaces

MAINTENANCE OF BRANCHES, REPRESENTATIVE OFFICES, RETAIL SPACE AND WAREHOUSES

- rent/sublease of office space;
- Rent retail space and warehouse

PROCEDURES FOR PRODUCT CONFORMITY TO REQUIREMENTS

- established technical regulations, standards, incl. standards of the organization, or the terms of contracts or confirmation of the right to carry out activities for the sale of goods abroad (certificates, permits, registration certificates, etc. documents)

SPECIALIZED CATALOGUE

- development, translation into foreign languages and publication

REGISTRATION PROCEDURES

- Trademarks (brand);
- on e-trading platforms

PROMOTING DOMESTIC PROCESSED GOODS TO FOREIGN MARKETS

WHO CAN GET A REFUND?

Enterprises that produce domestic processed goods (or a subsidiary that sells manufactured products), based on the List of domestic processed goods*

* With the exception of enterprises with state participation and their affiliated

WHERE CAN I SEE THE CONDITIONS, THE LIST OF DOCUMENTS?

Rules for reimbursement of part of the costs of subjects of industrial and innovative activities for the promotion of domestic processed goods, the list of domestic processed goods for which the costs of their promotion are partially reimbursed

HOW CAN I APPLY?

Via the Internet portal www.export.gov.kz (or www.qazindustry.gov.kz in the "business Support" section»)

HOW LONG DO YOU CONSIDER THE APPLICATION?

filing
electronical
application

20 min

Registration
of electronical
application *

10 min

Expertize
yes/no solution

7 w. d.

Commission's
review

7 w. d.

Sending the
Agreement

10 w. d.

**Total term
24 working
days**

**Appendix 2
to order**

**Order
Minister for Investment and
Development of RK
dated 30.11.2015 r. No. 1128**

**Application period
from March 12 to
November 23, 2020**

*The application is registered the day after it enters the system

Since the signing of the Cost recovery and cash recovery agreement
For 2 years, the implementation of counter-commitments has been monitored

MAJOR MISTAKES MADE IN THE FORMATION OF AN APPLICATION

REIMBURSEMENT OF PRODUCTIVITY COSTS

NON-COMPLIANCE BY CRITERIA:

- × non-refundable costs;
- × are not included in the refundable period, i.e. 24 months;
- × is not a priority sector of the economy;
- × is affiliated with state bodies and organizations;

ON THE PACKAGE OF DOCUMENTS:

- × incomplete set of documents;
- × documents in a foreign language without translation;
- × the application is not signed by the first Manager;
- × incorrect filling in of the application and report forms
 - invalid Manager data, registration data;the
 - labor productivity indicator is specified incorrectly;support measures received earlier are not specified;the
 - report does not contain a description of the need for services, results (expected effect), details and the amount of the contract are incorrectly specified;
- × references in the acts of work/services performed, invoices, and payment documents do not correspond to the contract details;
- × the acts do not contain a transcript of the signature and position of the parties who signed the act;
- × the name of the services rendered in the acts and invoices does not correspond to the subject of the agreement;
- × in payment documents, the payment purpose does not specify the number and date of the docks, or the docks to which the reference is made are not attached;
- × missing or poorly visible stamp of the Bank;
- × the amount of payment documents does not correspond to the contract amount;
- × the letter of credit is not a payment document

IMPROVING THE COMPANY'S COMPETENCE:

- × training exceeding 1 month;
- × staff who are not part of the technical engineering personnel, top managers are trained;
- × training, not on the issue of labor productivity improvement;
- × terms, topic, place of training, training organization do not comply with the order, contract and certificate of training;
- × does not comply with the purpose of recruiting foreign workers (improvement of technological processes and / or increase the efficiency of production organization);
- × the work experience of the foreign employee of at least 5 years is not confirmed;
- × payment docs do not indicate the month for which the foreign employee was paid;
- × no docs are attached for extra payment (payrolls, vacation orders, extra payments, bonuses, etc.);
- × discrepancies in submitted documents confirming the applicant's expenses for accommodation and travel:
 - documents are executed for an employee, not for an applicant;
 - there are no boarding passes or passes when traveling;
 - there are no supporting documents for accommodation;
 - no advance reports if the employee pays for accommodation and travel at the expense of business trips;

OPERATIONAL IMPROVEMENT :

- × submission of requests that do not provide for improvement of technological processes;
- × carrying out installation work on equipment not involved in the production process (for example, installation of video surveillance, fire or security alarm system, etc.).

IMPROVING THE EFFICIENCY OF PRODUCTION ORGANIZATION:

- × costs not related to improving the main production processes

! When submitting a repeated application based on the results of correcting comments, there is a submission of documents in the wording that does not correspond to the wording in previous applications (forgery, corrections, falsification).

MAJOR MISTAKES MADE IN THE FORMATION OF AN APPLICATION

PROMOTION OF DOMESTIC PROCESSED GOODS TO FOREIGN MARKETS

NON-COMPLIANCE BY CRITERIA:

- × are not producers of domestically-produced processed goods (or their subsidiaries);
- × arrears in taxes, duties and other mandatory payments;
- × affiliated with state authorities and organizations
- × are not included in the refundable period, i.e. on delivery of 12 months, on promotion of 32 months;

ON THE PACKAGE OF DOCUMENTS:

- × documents are not certified by a manager and a chief accountant with a transcript of the signature;
- × the invoices for payment and payment orders contain incorrect references to the Agreement;
- × incorrect filling in of the application;
- × do not document the transshipment of exported cargo from the railway wagons specified in the railway waybill;
- × documents in foreign language without translation;
- × poor quality copies of attached documents;

ON DELIVERY OF DOMESTIC PROCESSED GOODS

- × lack of documentation certifying the country of origin;
- × lack of contracts for the supply of goods, waybills, bill of lading, contract of lease (operation) of the container cargo wagon, receipts;
- × Absence of decoding to the certificates of works performed, which does not allow to determine whether the railway waybills belong to the certificates of works performed;
- × the absence of a certificate of transportation expenses during air transportation (with the air waybill number, cargo details, air transportation cost and flight type);
- × no bill of lading for sea transportation;
- × the waybill does not contain speedometer readings;
- × no reverse side of the bill of lading

FOR THE PROMOTION OF DOMESTIC PROCESSED GOODS

- × The places and dates of shooting are not specified in the photo reports about participation in foreign exhibitions, fairs, festivals;
- × lack of flight and accommodation docs, boarding passes, invoices and certificates of work performed for the purchase of air tickets and accommodation, as well as documents;
- × lack of original copies of advertising and handouts with a certificate of distribution of the catalog and their quantity;
- × lack of original newspapers with product advertising;
- × unplanned costs (event organization, training and consulting services);
- × lack of a travel card;
- × no invoices, certificate of work performed / services for the rental and production of the exhibition stand;
- × in payment orders, according to the value date, the money transfer is made on the early date of registration (formation) of applications for money transfer;
- × no work/service contract for direct participation in foreign exhibitions, fairs, festivals; × no work/service contract for direct participation in foreign exhibitions, fairs, festivals;
- × lack of documentation on registration of the representative office and documentation confirming the financing of the representative office.

! When submitting a repeated application based on the results of correcting comments, there is a submission of documents in the wording that does not correspond to the wording in previous applications (forgery, corrections, falsification).

QazIndustry

**HOW TO BECOME A MEMBER OF
SPECIAL ECONOMIC ZONE (SEZ)?**

SPECIAL ECONOMIC AND INDUSTRIAL ZONES OF THE REPUBLIC OF KAZAKHSTAN

"The Company "Kazakhstan Center for Industry and Exports" JSC with the announcement of the Government of the Republic of Kazakhstan on July 3, 2019 No. 469 is defined and acts as the Single Coordination Center for Special Economic and Industrial Areas in the Republic of Kazakhstan, which includes:

- Development and promotion of the SEZ/IZ
- Maintaining a unified register of SEZ participants and issuing certificates to participants
- Maintaining a unified register of IZ
- Improvement of legislation on SEZ and IZ
- Monitoring of indicators of SEZ participants
- Accompanying an interactive base
- Improving the performance of management companies
- Help to solve the problems of the participants of the SEZ and IZ

How to become a member of SEZ and IZ?



SPECIAL ECONOMIC ZONES OF THE REPUBLIC OF KAZAKHSTAN

SPECIAL ECONOMIC ZONES OF THE REPUBLIC OF KAZAKHSTAN

Special economic zone (SEZ) - part of the territory of the Republic of Kazakhstan, which has a special legal regime and infrastructure, for priority activities. There are 13 SEZ in Kazakhstan with different industry-oriented orientations

There are 13 SEZ in Kazakhstan with different industry-oriented orientations.

Preferences of the SEZ

TAX PREFERENCES

0% Corporate income tax
Land tax
Property tax

Customs preferences

Exemption from customs duties on imports

Land with infrastructure

Providing free land for the duration of the SEZ's existence

Affordable infrastructure



Priority land foreclosure right

Simplified hiring of foreign labour

For projects with more than \$1 million in investment.

MCI, attracting foreign labor is carried out outside quotas and without permits

Affordable infrastructure in the SEZ



INDUSTRIAL ZONES OF REPUBLIC OF KAZAKHSTAN

INDUSTRIAL ZONES OF REPUBLIC OF KAZAKHSTAN


Industrial zone (IZ) - territory provided with engineering and communication infrastructure provided to private business entities for the placement and operation of business activities, including in the field of industry, agro-industrial complex, tourism industry, transport logistics, waste management, in accordance with the legislation of the Republic of Kazakhstan.

There are 23 industrial zones in Kazakhstan.

Benefits of participating in industrial zones:

- Land supply (SD)
- Providing ready-made infrastructure
- The possibility of long-term lease or buyout of the SD at cadastral value
- No industry restrictions
- The possibility of signing an investment contract with the Commissioner (Ministry of Foreign Affairs of the Republic of Kazakhstan)

Affordable infrastructure in the IZ



Preferences at the conclusion of an investment contract

0% Corporate income tax (up to 10 years)
Land tax (up to 10 years)
Property tax (up to 8 years)

Exemption from customs duties

Customs duty of 0% to 5 years on imports:


- Technological equipment and components to it
- Spare parts, raw materials and materials

Grant in-kinds

Land, buildings, machinery and equipment for temporary free use

Simplified foreign labour procedure

Attracting foreign labour is carried out outside quotas and without permissions for employers to attract foreign labor





SPECIAL ECONOMICS ZONE PARK OF INNOVATIVE TECHNOLOGIES

SEZ «PIT» was created by the Decree of the President of the Republic of Kazakhstan on August 18, 2003 No.1166

Goals of creation of SEZ«PIT»:

Development of high-tech areas

Revitalization of the entry of the Economy of Kazakhstan into the world economic relations

Production of new products

Attracting investment

A special legal regime guarantees:

01 Tax and customs preferences

02 Special conditions for attracting foreign labour

03 Access to infrastructure

Priority sectors

2003-2028

Information technology	Electronics and instrumentation	Research in renewable energy
Telecommunications and communications	Development and Introduction of new materials	Education in Innovative Technology

- **corporate income tax**
- **property tax**
- **land tax**
- **social tax***
provided that the cost of labour is at least 70% of the total cost
- **VAT***
When goods are sold on the territory of the SEZ, fully consumed in the implementation of the activity
- **Exemption from customs duties for goods imported into the SEZ**



INFRASTRUCTURE

Common territory

163 Ha

13 464 m² office building

9 170 m² Production modules

4 636 m² Auxiliary facilities
(dining room, boiler room, TP and other engineering infrastructure)

87 га Vacant land


RESOURCE

Electricity
50,9 Mw

Link
To 100 Mbit/s

Water supply
8 301,89 m³/day

Gas supply
8 000 nm³/h



Transport accessibility


25 km
Almaty Business
Centre


20 km
railway station
Almaty-1 and 2


1 km
BAKAD
(by 2022)


15km
Airport
Almaty

NUMBER OF PARTICIPANTS IN THE PIT
SES IN THE TECHNOLOGICAL AREAS

170
Companies

121
Information
technology

31
Electronics and
instrumentation

8
telecommunications
and communications

4
Research in
renewable energy

3
Development and
introduction
new materials

3
Education
innovative
technologies

AIFC

**ASTANA INTERNATIONAL
FINANCIAL CENTRE**



Welcome to Astana International Financial Centre (AIFC)

AIFC plays a pivotal role in positioning itself as a global centre for business and finance, connecting the economies of:

- ✓ The Central Asia
- ✓ The Caucasus
- ✓ EAEU
- ✓ West China
- ✓ Mongolia
- ✓ Middle East
- ✓ Europe



Potential of AIFC

"Financial Gates"

AIFC is well-placed to become Eurasian gate providing trade and financial flows between East and West countries. In the Global Competitiveness Index of the World Economic Forum 2019, Kazakhstan ranked 55th out of 141, taking second place among countries in the Eurasian region.

"Belt and Road Initiative"

The Belt and Road Initiative (BRI), an unprecedented strategy aimed at reviving the ancient Silk Road, plays a great role in strengthening trade and political relations between Europe and Asia. Strategically located and business friendly Kazakhstan – often referred to as the "Buckle" of the Belt and Road Initiative – is a key recipient of transport-related BRI projects.

Privatisation of State Enterprises

About 40 large national companies and 160 subsidiaries and affiliates of the Sovereign Wealth Fund "Samruk-Kazyna" have been identified to be proposed for transfer to the competitive environment as part of the Comprehensive Privatisation Plan for 2016-2020, approved by the Government of the Republic of Kazakhstan. The Astana International Exchange is defined as the main platform for the privatization of national companies.



A summary of the benefits of AIFC

Liberalized Currency Control

Transactions of AIFC Participants may be denominated and executed in a currency agreed between them. Trades at Astana International Exchange are to be denominated and executed in US dollars, euro, RNB, rubles & tenge.

Worldwide Regulatory Standards & AIFC Court

AIFC law is developed based on experience of common law countries. The AIFC Court is the region's first independent common law court system for the resolution of civil and commercial disputes.

English Language

The official language of AIFC is English. AIFC Acts, court proceedings, records, all transactions, responses to requests must be in English.

Preferential Tax Regime

AIFC participants and their foreign employees are exempted from corporate tax income received from providing the financial and ancillary services (ancillary or consulting services provided to companies with regulated activities), from capital gains as well as from dividends and income from the increase in value when selling securities that are on the date of sale in the official lists of the stock exchange until 2066.

Redomiciliation

AIFC has acts that allow the transfer of companies from other jurisdictions. On December 24, 2019, Kazakhstan Energy Reinsurance Company Ltd. redomiciled from Bermuda to the AIFC.

Recognized Stock Exchange

In 2019 the United Kingdom's HM Revenue and Customs granted the Astana International Exchange "Recognized Stock Exchange" status.

Special organizational-legal forms

There are 15 types of organizational-legal forms for incorporating new legal entities. A company can be created with a share capital of 1 USD.

Visa support

AIFC provides visa support to foreign citizens on a "one-stop-shop" basis

Tax exemptions

Tax exemptions for AIFC Participants on certain types of activities

Exemption from CIT and VAT until 1 January 2066 for AIFC participants on income from providing financial services:

- Islamic banking services;
- reinsurance and insurance brokerage services;
- investment management services for assets of investment fund;
- brokerage, dealer or underwriting services;
- any other financial services prescribed by a joint act of the AIFC, Ministry of National Economy, and Ministry of Finance*.

Exemption from CIT until 1 January 2066 for AIFC participants on income from legal, audit, accounting, consulting services provided to:

- AIFC Bodies;
- AIFC Participants that provide financial services prescribed by the Constitutional Statute

AIFC Participants that provide financial and auxiliary services, prescribed by the Constitutional Statute, are exempt from property tax and land tax for facilities located in the AIFC

Foreign nationals who are Employees of an AIFC Participant are exempt from PIT on income received under their employment contracts with the AIFC Participant that provides financial and auxiliary services, prescribed by the Constitutional Statute.

Tax exemptions for shareholders and company founders registered in the AIFC, regardless of their activities

Until 1 January 2066, legal and natural persons (any) are exempt from personal and corporate income tax on income received from the following:

- profits from the sale of shares of AIFC Participants that are legal persons registered under the Acting Law of the AIFC or stakes in the capital of AIFC Participants that are legal persons registered under the Acting Law of the AIFC;
- dividends from shares of AIFC Participants that are legal persons registered under the Acting Law of the AIFC or stakes in the capital of AIFC Participants that are legal persons registered under the Acting Law of the AIFC

2

Tax exemptions for securities listed on the official list of the Stock Exchange

Until 1 January 2066, legal and natural persons (any) are exempt from personal and corporate income tax on income received from the following:

- Profits from the sale of securities listed, on the day of their sale, on the official list of the AIX;
- dividends and interest from securities listed, on the day of their accrual, on the official list of the AIX.

3



SUPPORT TOOLS "BAITEREK" HOLDING

«Kazakhstan Project Preparation Fund»:

- partial or complex development of pre-project documentation (feasibility study, business plan, Fin. model), involving highly qualified consultants;
- -co-financing of the pre-project stage on a payback basis when raising investment and/or borrowed capital;
- consulting support of projects, structuring, attraction of strategic or financial investors.

Support conditions:

- 1) Total cost of the project - at least 4 billion tenge;
- 2) the cost of KPPF services depends on the level of project development and

«Development Bank of Kazakhstan»:

- lending/guaranteeing the investment project.

Support conditions:

1. minimum loan amount - 7 billion tenge;
2. loan term - from 5 to 20 years;
3. The amount of the Applicant's own participation - at least 20% of the investment project estimate;
- 4.1) financing rate - no more than 11% within the framework of SPIIR;
- 4.2) financing rate - 6% under DKB-2025 / Economics of Simple Things (including subsidies from Damu Fund);
- 4.3) the interest rate for granting a guarantee - depending on the project risks (approximately 3-4% per annum)
- 5) Pledge security: at least 30% of the loan amount are "hard" mortgages, 70% are assets received in the future. Translated with

«Kazyna Capital Management»:

equity financing under the Programme of Preferential Financing. Terms and conditions of support:

Financing.Terms and conditions of support:

1. participation in the capital of the company - up to 49%;
2. The amount of investments - up to 5 billion tenge (investments up to 1 billion tenge are made through BVI);
3. investment period - up to 9 years;
4. Interest rate - 8% per annum; conclusion of an agreement on repurchase of shares from a creditworthy

- equity / debt / mezzanine financing outside the Programme of preferential financing.

Support conditions:

1. participation in the capital of the company - up to 49%;
2. amount of investments - from KZT 500 million;
3. investment period - up to 10 years;
4. interest rate - depending on the project risks (approximately 12-16% per annum);
5. conclusion of an agreement on repurchase of shares by a creditworthy shareholder/partner/affiliated company.

«Industrial Development Fund»:

leasing financing for the purchase of equipment.

Support conditions:

- 1) Cost of equipment - from 80 million tenge;
- 2) leasing term - up to 10 years;
- 3) The size of the Applicant's own participation (advance payment) - at least 15% of the value of the leasing object;
- 4) financing rate - 5% within SPIIR.
- 5) additional collateral in case the advance payment is insufficient

«Kazakhstan Project Preparation Fund»:

- partial or complex development of pre-project documentation (feasibility study, business plan, Fin. model), involving highly qualified consultants;

- co-financing of the pre-project stage on a payback basis when raising investment and/or borrowed capital;

-consulting support of projects, structuring, attraction of strategic or financial investors.

Support conditions:

- 1) Total cost of the project - at least 4 billion tenge;
- 2) the cost of KPPF services depends on the level of project development and

«Development Bank of Kazakhstan»:

- lending/guaranteeing the investment project.

Support conditions:

- minimum loan amount - 7 billion tenge;
- loan term - from 5 to 20 years;
- The amount of the Applicant's own participation - at least 20% of the investment project estimate;

4.1) financing rate - no more than 11% within the framework of SPIIR;

4.2) financing rate - 6% under DKB-2025 / Economics of Simple Things (including subsidies from Damu Fund);

4.3) the interest rate for granting a guarantee - depending on the project risks (approximately 3-4% per annum)

5) Pledge security: at least 30% of the loan amount are "hard" mortgages, 70% are assets received in the future. Translated with

«DAMU» Entrepreneurship Development Fund» JSC

subsidising part of the loan interest rate.

Support conditions within the framework of DKB-2025:

1.1) The amount of the BVU loan - no more than 7 billion tenge;

1.2) DBK loan amount - not limited;

2.1) Subsidy period under the BVU loan - for investments - 5 years, POS - 3 years;

2.2) subsidy period under the loan in DBK - without limitation of subsidy period. At the same time, DBK projects with a subsidy period of more than 5 years are allowed to be subsidised on the recommendation of the State Commission for Economic Modernisation;

3.1) the financing rate through the BWA - 6% per annum (final). Subsidies are granted only for loans with a nominal interest rate not exceeding the basic interest rate (9%) set by the NBRK and increased by 5 (five) percentage points (of which 6% is paid by the entrepreneur and the difference is subsidised by the state);

3.2) financing rate through the DBK - 6% per annum (final). At the same time, subsidising the interest rate on DBK loans is carried out with a nominal interest rate not exceeding 15% (of which 6% is paid by the private entrepreneur and the difference is subsidised by the government).

Terms and conditions of support under the Economics of Simple Things:

- compliance with the list of products manufactured in accordance with the appendix to the Mechanism (PP RK № 820 11.12.2018);
- subsidy period - for investments of 10 years, PIC - 3 years;
- financing rate - 6% p.a. (final). The loan interest rate is subsidised at a nominal interest rate of no more than 15% (of which 6% is paid by a private business entity and the difference is subsidised by the government). Translated with

«DAMU» Entrepreneurship Development Fund» JSC - partial loan

partial loan guarantee.

Support conditions as part of DKB-2025:

1.1) Guarantee amount - up to 50% of the loan amount. In this case, the maximum loan amount should not exceed 1 billion tenge;

1.2) Guarantee amount - up to 85% of the loan amount. At that, the maximum loan amount should not exceed KZT 360 million;

2) Guarantee may be provided only for BLR loans with nominal interest rate not exceeding the base rate of the NBRK (9%) increased by 5 (five) percentage points, and for BLR loans - with interest rate not exceeding 15% per annum.

Terms and conditions of support under the Economics of Simple Things:

1) compliance with the list of products manufactured in accordance with the appendix to the Mechanism (PP RK № 820 11.12.2018);

2) loans with nominal interest rate not exceeding 15% per annum are subject to guarantee.

3.1) Guarantee amount - 50% of the loan amount up to 3 billion tenge inclusive;

3.2) Guarantee amount - 30% for loans above 3 billion KZT to 5 billion KZT inclusive;

CONTACTS LIST

Organizations	Contact telephone, address	E-mail, web-site
«SK-Pharmaceuticals» LLP	+7 (7172) 559707-head of the Department for support of suppliers and Domestic Manufacturers (Zhakipova E.) +7 (7172) 559247-head of the Department for providing medical devices (Palinka N.,) Nur-Sultan city, Dostyk str.13/3	info@sk-pharmacy.kz sk-pharmacy.kz
JSC "National Company "KAZAKH INVEST"	+7 (7172) 620 620 Nur-Sultan city, Mangilik yel, bld. 55/20, block C 4.1	info@invest.gov.kz invest.gov.kz
JSC «Qazindustry»	+ 7 (7172) 79 33 99 Nur-Sultan city, Kabanbay batyr ave., 17,(Block E), 4-5 levels	info@qazindustry.gov.kz qazindustry.gov.kz
Ministry of Industry and infrastructural development of the Republic of Kazakhstan	+7 (7172) 983-135 Nur-Sultan city, Kabanbay batyr ave., 32/1, entrance from the side of Kunaev str.	miid@miid.gov.kz www.gov.kz
Republican State Enterprise on the Right of Economic Management "National Center for Expertise of Medicines and Medical Devices" of the Ministry of Health of the RK	+7 (7172) 78-99-07 Nur-Sultan city, 010000, Bauyrzhan Momyshuly ave., 2/3	www.ndda.kz farm@dari.kz support@dari.kz
Management Company "Atyrau Technopark" LLP	+7 727 320 18 21 +7 727 320 18 56 +7 727 320 18 57 050032, Almaty, Medeu district Alatau microdistrict, Ibragimov str	info@aitc.kz
ASTANA INTERNATIONAL FINANCIAL CENTRE	+7 707 111 30 04 - Senior Manager of the Investment Attraction Department (E. Ten) Nur-Sultan city, 010000 Ave. Мәңгілік Yel, 55/18, Pavilion 3.3	www.aifc.kz info@aifc.kz Ye.Ten@aifc.kz
"BAITEREK" HOLDING	+7 (7172) 907 800; 8 (7172) 919 111; +7 (7172) 919 110 +7 (7172) 270 416 (0416); +7 778 964 90 41 - Director of the Project Finance Department (A.E. Tazhikenov). Nur-Sultan city, 010000, Yesil district, Mangilik Yel Ave. 55A	kense@baiterek.gov.kz A.tazhikenov@baiterek.gov.kz